<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Biomed Sci</journal-id><journal-id journal-id-type="pmc-domain-id">857</journal-id><journal-id journal-id-type="pmc-domain">jbiomedsci</journal-id><journal-title-group><journal-title>Journal of Biomedical Science</journal-title></journal-title-group><issn pub-type="ppub">1021-7770</issn><issn pub-type="epub">1423-0127</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7749790</article-id><article-id pub-id-type="pmcid-ver">PMC7749790.2</article-id><article-id pub-id-type="pmcaid">7749790</article-id><article-id pub-id-type="pmcaiid">7749987</article-id><article-id pub-id-type="pmid">33341119</article-id><article-id pub-id-type="doi">10.1186/s12929-020-00695-2</article-id><article-id pub-id-type="publisher-id">695</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Coronavirus vaccine development: from SARS and MERS to COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Li</surname><given-names initials="YD">Yen-Der</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chi</surname><given-names initials="WY">Wei-Yu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="JH">Jun-Han</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferrall</surname><given-names initials="L">Louise</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hung</surname><given-names initials="CF">Chien-Fu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1623-4584</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="TC">T.-C.</given-names></name><address><email>wutc@jhmi.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Molecular and Cellular Biology, </institution><institution>Harvard University, </institution></institution-wrap>Cambridge, MA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>Department of Pathology, School of Medicine, </institution><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>Johns Hopkins School of Medicine, </institution></institution-wrap>1550 Orleans St, CRB II &#8211; Room 309, Baltimore, MD 21287 USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>27</volume><issue-id pub-id-type="pmc-issue-id">348841</issue-id><elocation-id>104</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>12</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>21</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-01 12:25:16.807"><day>01</day><month>10</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">7749790</article-id><article-id pub-id-type="doi">10.1186/s12929-020-00695-2</article-id><article-version>1</article-version><pub-date><day>20</day><month>12</month><year>2020</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">7749987</article-id><article-id pub-id-type="doi">10.1186/s12929-020-00695-2</article-id><article-version>2</article-version><pub-date><day>20</day><month>12</month><year>2020</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12929_2020_Article_695.pdf"/><abstract id="Abs1"><p id="Par1">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Coronaviruses</kwd><kwd>Vaccine</kwd><kwd>Vaccine development</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par33">Coronaviruses (CoVs) are a group of related viruses that can cause respiratory tract infection in humans ranging from mild symptoms to lethal outcomes. Until now, there are seven genera of CoVs that are known to infect humans [<xref ref-type="bibr" rid="CR1">1</xref>]. Four of these genera, including Human Coronavirus 229E (HCoV-229E), Human Coronavirus OC43 (HCoV-OC43), Human Coronavirus NL63 (HCoV-NL63), and Human Coronavirus HKU1 (HCoV-HKU1), only cause relatively mild and self-limiting respiratory symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. Alternatively, the other three CoVs, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are highly pathogenic and can lead to severe respiratory diseases and fatal outcome in infected patients. The first lethal coronavirus SARS-CoV emerged in 2002 in Guangdong Province, China. During the 2002&#8211;2004 outbreak, SARS-CoV had infected 8,098 people and resulted in 774 SARS-associated deaths (~&#8201;10% mortality rate) across 29 countries before it disappeared [<xref ref-type="bibr" rid="CR3">3</xref>]. In 2012, MERS-CoV emerged in Saudi Arabia. It caused two outbreaks in South Korea in 2015 and in Saudi Arabia in 2018, and still has ongoing reports of sporadic cases nowadays. As of January 2020, there are 2,519 confirmed MERS cases and 866 deaths (~&#8201;35% mortality rate) across 27 countries [<xref ref-type="bibr" rid="CR4">4</xref>]. In December 2019, a new type of CoV that can cause severe respiratory illness emerged in Wuhan, China. The World Health Organization named this novel virus SARS-CoV-2 and the disease COVID-19, or Coronavirus Disease 2019. The clinical manifestation of COVID-19 can vary from asymptomatic and mild flu-like symptoms to acute respiratory distress syndrome and death. Long-term pulmonary, cardiological, and neurological complications have also been reported in COVID-19 cases [<xref ref-type="bibr" rid="CR5">5</xref>]. Compared with SARS-CoV and MERS-CoV, SARS-CoV-2 is highly contagious with an estimated reproductive number of 2.2 (one existing COVID-19 case can cause an average of 2.2 new infections) [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition, its ability to spread through asymptomatic patients has posed a great challenge to containment measures [<xref ref-type="bibr" rid="CR7">7</xref>]. By October 2020, SARS-CoV-2 has infected more than 43 million individuals and resulted in about 1.15 million deaths (~&#8201;3% mortality rate) in 235 countries, areas or territories worldwide [<xref ref-type="bibr" rid="CR8">8</xref>]. Needless to say, COVID-19 has become the most serious public health crisis of our generation and has a profound impact on the global economy and geopolitics. Although our understanding of pathogenic CoVs has been steadily accumulating for about two decades, no effective vaccine has yet been approved for the prevention of human CoV infection. Considering the rapid spread and high mortality of COVID-19, an effective vaccine is urgently needed to control this pandemic. In this review, we summarize relevant CoV biology, SARS and MERS immunization strategies, and recent efforts of COVID-19 vaccine development. We hope this review can provide essential knowledge for any researcher who is interested in COVID-19 vaccine development.</p></sec><sec id="Sec2"><title>Coronavirus biology and its implication on vaccine development</title><p id="Par34">Coronaviruses, whose name derives from their characteristic crown-like appearance under the electron microscope, are enveloped RNA viruses with a diameter of approximately 80&#8211;160&#160;nm [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The genome of CoVs is a&#8201;~&#8201;30&#160;kb single-stranded positive-sense RNA molecule, which is the largest genome of all known RNA viruses [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. The 5&#8242;-terminus of the CoV genome contains two overlapping open reading frames (ORFs): ORF 1a and ORF 1b, spanning two-thirds of the genome length (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. ORF 1a and ORF 1ab can be translated into two polyproteins (pp), pp1a and pp1ab, which are further cleaved into 16 non-structural proteins (Nsps) involved in viral genome replication and subgenomic mRNA synthesis [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. The 3&#8242;-terminus of the CoV genome encodes four major structural proteins in the order of spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. S, E, M protein forms the envelope of the CoV, while N protein forms the capsid to pack genomic RNA (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b) [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. The 3&#8242;-terminus of the genome also encodes multiple accessory proteins, which are usually genus-specific and can help CoV evade the immune system or increase virulence [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. For instance, SARS-CoV contains accessory protein ORF 3a, 3b, 6, 7a, 7b, 8a, 8b and 9b, MERS-CoV contains ORF 3, 4a, 4b, 5, 8b, and SARS-CoV-2 contains ORF 3a, 6, 7a, 7b, 8, 10 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The genome and virion structure of coronaviruses (CoVs). <bold>a</bold> The genome structure of SARS-CoV, MERS-CoV, and SARS-CoV-2 [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. The 5&#8242;-terminus of the CoV genome contains two overlapping open reading frames (ORFs): ORF 1a and ORF 1b, spanning two-thirds of the genome length. ORF 1a and ORF 1ab can be translated into two polyproteins (pp), pp1a and pp1ab, which are further cleaved into 16 non-structural proteins (Nsps). The 3&#8242;-terminus of the CoV genome encodes four major structural proteins in the order of spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Genus-specific accessory proteins are also encoded at the 3&#8242;-terminus of the CoV genome. <bold>b</bold> The virion structure of SARS-CoV-2 [<xref ref-type="bibr" rid="CR16">16</xref>]. The spike (S), envelope (E), membrane (M) proteins form the envelope of the CoV, and the nucleocapsid (N) proteins form the capsid to pack the genomic RNA. The spike protein binds to angiotensin converting enzyme 2 (ACE2) on the cell membrane, which allows the virus to enter the cell. (Created with BioRender.com.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12929_2020_695_Fig1_HTML.jpg"/></fig></p><p id="Par35">Many viral proteins are essential for the life cycle of CoVs. For entering target cells, S protein first binds to cellular receptors through its receptor-binding domain (RBD), and the receptor-virus complex is subsequently translocated to endosomes (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR15">15</xref>]. Both SARS-CoV and SARS-CoV-2 S proteins bind to angiotensin-converting enzyme 2 (ACE2), while the S protein of MERS-CoV uses dipeptidyl peptidase-4 (DPP4) as its cellular receptor (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b) [<xref ref-type="bibr" rid="CR16">16</xref>]. At the endosome, S protein is further cleaved into S1 (RBD-containing) and S2 (non-RBD-containing) subunits, and the S2 subunit mediates fusion between the viral envelope and the host cell membrane [<xref ref-type="bibr" rid="CR15">15</xref>]. After entering the cell, several Nsps, particularly RNA&#8208;dependent RNA polymerase (Nsp12) and helicase (Nsp13), mediate the replication of the CoV genome and the transcription of CoV mRNA [<xref ref-type="bibr" rid="CR17">17</xref>]. The CoV mRNA is further translated into different nonstructural and structural proteins. The N proteins bind to CoV genomic RNA to form viral nucleocapsids, and S, E, M proteins form the envelope of CoV [<xref ref-type="bibr" rid="CR15">15</xref>]. After assembly, viral particles bud through an endoplasmic reticulum (ER)-Golgi pathway and exit the cells by exocytosis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR15">15</xref>].<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The life cycle of SARS-CoV-2 [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Upon binding to the membrane receptor ACE2, SARS-CoV-2 virion enters the host cell and releases its plus-strand RNA genome. The plus-strand RNA translates pp1a and pp1ab, which are further cleaved into multiple non-structural proteins (Nsps) including an RNA-dependent RNA polymerase (Nsp12). The RNA-dependent RNA polymerase transcribes a negative-strand genomic RNA, and then uses this negative-strand genomic RNA as template to generate more plus-strand genomic RNA (genomic replication) and many different subgenomic RNAs (subgenomic transcription). The subgenomic RNAs are further translated into major structural proteins (N, S, M, E), which will assemble with plus-strand genomic RNA to form a mature virion in lumen of the ER. Finally, the whole virus leaves the cell through exocytosis. (Reprinted from &#8220;Coronavirus Replication Cycle&#8221;, by BioRender.com (2020). Retrieved from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://app.biorender.com/biorender-templates">https://app.biorender.com/biorender-templates</ext-link>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12929_2020_695_Fig2_HTML.jpg"/></fig></p><p id="Par36">The S protein is particularly important for virus-cell receptor binding and virus-cell membrane fusion, suggesting that it can be an effective target for CoV vaccine design [<xref ref-type="bibr" rid="CR15">15</xref>]. In fact, studies have shown that antibodies generated against the S protein are long-lasting and immunodominant in recovered SARS patients [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In addition, several studies have demonstrated that the anti-S antibody can neutralize SARS-CoV and MERS-CoV and provides protective effects in animals and humans [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, many S protein-based vaccines against SARS-CoV and MERS-CoV have been shown to elicit potent immune responses and protective effects in preclinical models [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. These results corroborate that CoV S protein serves as an ideal vaccine target to induce neutralizing antibodies and protective immunity. Besides S protein, other structural proteins have also been tested as vaccine targets. N protein-based vaccines usually cannot induce neutralizing antibodies, likely due to the fact that N protein is not displayed on the CoV surface [<xref ref-type="bibr" rid="CR16">16</xref>]. However, N protein has the advantage of being more conserved across CoV species than S protein, making it a potential target for a T-cell inducing, universal CoV vaccine [<xref ref-type="bibr" rid="CR16">16</xref>]. One recent study has shown that a viral vector vaccine expressing N protein can induce CD4+&#8201;T cell-dependent protection against SARS-CoV and MERS-CoV, suggesting the feasibility of N protein-based T-cell inducing CoV vaccines [<xref ref-type="bibr" rid="CR28">28</xref>]. M protein-based vaccines, on the other hand, can induce a high titer of antibody response in immunized animals [<xref ref-type="bibr" rid="CR29">29</xref>]. However, no neutralization antibody or protective immunity data of M protein-based vaccines in preclinical models have been demonstrated. Finally, very few CoV E protein-based immunization studies have been reported so far, and none of the studies demonstrated induction of neutralizing antibodies or protective immunity [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par37">There are also immunopathological complications associated with the SARS-CoV and MERS-CoV vaccines that require addressing and further optimization. One adverse effect is the induction of antibody-dependent enhancement (ADE) effect, which is usually caused by vaccine-induced suboptimal antibodies that facilitates viral entry into host cells [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. A study found that SARS-CoV vaccine based on full-length S protein enhances SARS-CoV infection of human cell lines in vitro [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, two studies have also shown that anti-S protein serum results in increased viral infectivity of SARS-CoV [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. These results raise safety concerns for S protein-based SARS-CoV and MERS-CoV vaccines. One potential strategy to overcome the ADE problem is to design vaccines that only contain major neutralizing epitopes, such as the S1 subunit or the RBD domain of the S protein. This strategy can decrease the induction of non-neutralizing antibodies by CoV vaccines and therefore reduce the ADE effect. Another potential adverse effect is vaccine-induced eosinophilic immunopathology, which is an unwanted Th2-skewed immune response elicited by vaccination [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. At least two studies have reported that whole inactivated virus vaccine of SARS-CoV induces eosinophilic proinflammatory pulmonary response after mice challenged with SARS-CoV [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. In addition, one study also reported that immunization with SARS-CoV virus-like particle (VLP) vaccine leads to eosinophilic immunopathology in the lung after viral challenge [<xref ref-type="bibr" rid="CR37">37</xref>]. In order to prevent this Th2-type immunopathology, a few studies have worked on adjuvant optimization. They found that appropriate adjuvants, such as Toll-like receptor agonist and delta-inulin polysaccharide, can increase serum neutralizing antibody titers and reduce lung eosinophilic immunopathology [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Their results provide a promising strategy to deal with Th2-skewed immune response induced by some CoV vaccines.</p></sec><sec id="Sec3"><title>Previous progress of SARS-CoV and MERS-CoV immunization strategies</title><p id="Par38">Various forms of vaccines targeting SARS-CoV and MERS-CoV have been developed and tested in preclinical models. However, only a few of them entered clinical trials and none of them have been FDA approved. These approaches include protein subunit vaccines, virus-like particle vaccines, DNA vaccines, viral vector vaccines, whole-inactivated vaccines and live-attenuated vaccines. The following sections outline the principles of various forms of SARS-CoV and MERS-CoV vaccine development (Table <xref rid="Tab1" ref-type="table">1</xref>), and the latest results from both preclinical studies and clinical trials (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Advantages and disadvantages of different vaccine platforms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Vaccine platform</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th><th align="left" colspan="1" rowspan="1">Clinically approved examples</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Whole inactivated virus vaccine</td><td align="left" colspan="1" rowspan="1">Stronger immune response; Safer than live attenuated virus</td><td align="left" colspan="1" rowspan="1">Potential epitope alteration by inactivation process</td><td align="left" colspan="1" rowspan="1">Typhoid, Cholera, Hepatitis A&#160;virus, Plague, Rabies, Influenza, Polio (Salk)</td></tr><tr><td align="left" colspan="1" rowspan="1">Live attenuated virus vaccine</td><td align="left" colspan="1" rowspan="1">Stronger immune response; Preservation of native antigen; Mimicking natural infection</td><td align="left" colspan="1" rowspan="1">Risk of residual virulence, especially for immunocompromised people</td><td align="left" colspan="1" rowspan="1">Measles, Mumps, Polio (Sabin), Rota virus, Yellow Fever, Bacillus Calmette&#8211;Gu&#233;rin (BCG), Rubella, Varicella</td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="1" rowspan="1">Stronger immune response; Preservation of native antigen; Mimicking natural infection</td><td align="left" colspan="1" rowspan="1">More complicated manufacturing process; Risk of genomic integration; Response dampened by pre-existing immunity against vector</td><td align="left" colspan="1" rowspan="1">Ebola virus</td></tr><tr><td align="left" colspan="1" rowspan="1">Subunit vaccine</td><td align="left" colspan="1" rowspan="1">Safe and well-tolerated</td><td align="left" colspan="1" rowspan="1">Lower immunogenicity; Requirement of adjuvant&#160;or conjugate&#160;to increase immunogenicity</td><td align="left" colspan="1" rowspan="1">Pertussis,&#160;Influenza, <italic toggle="yes">Streptococcus pneumoniae,&#160;Haemophilus influenzae type b</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral-like particle vaccine</td><td align="left" colspan="1" rowspan="1">Safe and well-tolerated; mimicking native virus conformation</td><td align="left" colspan="1" rowspan="1">Lower immunogenicity; More complicated manufacturing process</td><td align="left" colspan="1" rowspan="1">Hepatitis B virus, Human Papillomavirus</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="1" rowspan="1">Safe and well-tolerated; Stable under room temperature; Highly adaptable to new pathogen; Native antigen expression</td><td align="left" colspan="1" rowspan="1">Lower immunogenicity; Difficult administration route; Risk of genomic integration</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">RNA vaccine</td><td align="left" colspan="1" rowspan="1">Safe and well-tolerated; Highly adaptable to new pathogen; Native antigen expression</td><td align="left" colspan="1" rowspan="1">Lower immunogenicity; Requirement of&#160;low temperature storage and transportation;&#160;Potential risk of RNA-induced interferon response</td><td align="left" colspan="1" rowspan="1">NA</td></tr></tbody></table></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Clinical trials of SARS, MERS and COVID-19 vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Platform</th><th align="left" colspan="2" rowspan="1">Vaccine</th><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Status</th><th align="left" colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><bold><italic toggle="yes">SARS Vaccine Clinical Trials</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="2" rowspan="1">Inactivated SARS-CoV vaccine (ISCV)</td><td align="left" colspan="1" rowspan="1">Sinovac</td><td align="left" colspan="1" rowspan="1">Phase I, completed</td><td align="left" colspan="1" rowspan="1"><p>Lin et al. (2007) [<xref ref-type="bibr" rid="CR110">110</xref>]</p><p>No NCT ID</p></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="2" rowspan="1">VRC-SRSDNA015-00-VP</td><td align="left" colspan="1" rowspan="1">NIAID</td><td align="left" colspan="1" rowspan="1">Phase I, completed</td><td align="left" colspan="1" rowspan="1"><p>Martin et al. (2008) [<xref ref-type="bibr" rid="CR65">65</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00099463">NCT00099463</ext-link></p></td></tr><tr><td align="left" colspan="6" rowspan="1"><bold><italic toggle="yes">MERS Vaccine Clinical Trials</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="2" rowspan="1">GLS-5300 (INO-4700)</td><td align="left" colspan="1" rowspan="1">GeneOne Life Science/Inovio Pharmaceuticals/International Vaccine Institute</td><td align="left" colspan="1" rowspan="1">Phase I, completed</td><td align="left" colspan="1" rowspan="1"><p>Modjarrad et al. (2019) [<xref ref-type="bibr" rid="CR69">69</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02670187">NCT02670187</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="2" rowspan="1">GLS-5300 (INO-4700)</td><td align="left" colspan="1" rowspan="1"><p>GeneOne Life Science/Inovio Pharmaceuticals/</p><p>International Vaccine Institute</p></td><td align="left" colspan="1" rowspan="1">Phase I/IIa, completed</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03721718">NCT03721718</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">MVA-MERS-S</td><td align="left" colspan="1" rowspan="1">CTC North GmbH &amp; Co. KG</td><td align="left" colspan="1" rowspan="1">Phase I, completed</td><td align="left" colspan="1" rowspan="1"><p>Koch et al. (2020) [<xref ref-type="bibr" rid="CR102">102</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03615911">NCT03615911</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">MVA-MERS-S_DF1</td><td align="left" colspan="1" rowspan="1">CTC North GmbH &amp; Co. KG</td><td align="left" colspan="1" rowspan="1">Phase Ib, not yet recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04119440">NCT04119440</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">ChAdOx1 MERS</td><td align="left" colspan="1" rowspan="1">University of Oxford</td><td align="left" colspan="1" rowspan="1">Phase I, recruiting</td><td align="left" colspan="1" rowspan="1"><p>Folegatti et al. (2020) [<xref ref-type="bibr" rid="CR98">98</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03399578">NCT03399578</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">ChAdOx1 MERS</td><td align="left" colspan="1" rowspan="1">King Abdullah International Medical Research Center/University of Oxford</td><td align="left" colspan="1" rowspan="1">Phase I, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04170829">NCT04170829</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">BVRS-GamVac-Combi</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology/Acellena Contract Drug Research and Development</td><td align="left" colspan="1" rowspan="1">Phase I/II, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04128059">NCT04128059</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector vaccine</td><td align="left" colspan="2" rowspan="1">BVRS-GamVac</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology</td><td align="left" colspan="1" rowspan="1">Phase I/II, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04130594">NCT04130594</ext-link></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Platform</th><th align="left" colspan="1" rowspan="1">Vaccine</th><th align="left" colspan="1" rowspan="1">Vaccine type</th><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Status</th><th align="left" colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><bold><italic toggle="yes">COVID-19 Vaccine Clinical Trials</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">NVX-CoV2373</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 rS/Matrix-M1 Adjuvant</td><td align="left" colspan="1" rowspan="1">Novavax</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Keech et al. (2020) [<xref ref-type="bibr" rid="CR132">132</xref>]</p><p>2020-004123-16</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">mRNA-1273</td><td align="left" colspan="1" rowspan="1">LNP-encapsulated mRNA</td><td align="left" colspan="1" rowspan="1">Moderna/NIAID</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Jackson et al. (2020) [<xref ref-type="bibr" rid="CR140">140</xref>]</p><p>Anderson et al. (2020) [<xref ref-type="bibr" rid="CR141">141</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1"><p>BNT162b1</p><p>BNT162b2</p></td><td align="left" colspan="1" rowspan="1">LNP-mRNAs</td><td align="left" colspan="1" rowspan="1">BioNTech/Fosun Pharma/Pfizer</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Mulligan et al. (2020) [<xref ref-type="bibr" rid="CR144">144</xref>]</p><p>Sahin et al. (2020) [<xref ref-type="bibr" rid="CR145">145</xref>]</p><p>Walsh et al. (2020) [<xref ref-type="bibr" rid="CR146">146</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">AZD1222</td><td align="left" colspan="1" rowspan="1">ChAdOx1-S</td><td align="left" colspan="1" rowspan="1">University of Oxford/AstraZeneca</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Folegatti et al. (2020) [<xref ref-type="bibr" rid="CR99">99</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540393">NCT04540393</ext-link></p><p>ISRCTN89951424</p><p>CTRI/2020/08/027170</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Ad5-nCoV</td><td align="left" colspan="1" rowspan="1">Adenovirus Type 5</td><td align="left" colspan="1" rowspan="1">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Zhu et al. (2020) [<xref ref-type="bibr" rid="CR92">92</xref>]</p><p>Zhu et al. (2020) [<xref ref-type="bibr" rid="CR93">93</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526990">NCT04526990</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540419">NCT04540419</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Gam-COVID-Vac</td><td align="left" colspan="1" rowspan="1">Adeno-based (rAd26-S&#8201;+&#8201;rAd5-S)</td><td align="left" colspan="1" rowspan="1">Gamaleya Research Institute</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Logunov et al. (2020) [<xref ref-type="bibr" rid="CR151">151</xref>]</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04564716">NCT04564716</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Ad26.COV2.S</td><td align="left" colspan="1" rowspan="1">Adeno-based</td><td align="left" colspan="1" rowspan="1">Janssen Pharmaceutical Companies</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">Adsorbed COVID-19 (inactivated) Vaccine</td><td align="left" colspan="1" rowspan="1">inactivated</td><td align="left" colspan="1" rowspan="1">Sinovac</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04582344">NCT04582344</ext-link></p><p>669/UN6.KEP/EC/2020</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine (Vero cell)</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Wuhan Institute of Biological Products/Sinopharm</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Xia et al. (2020) [<xref ref-type="bibr" rid="CR154">154</xref>]</p><p>ChiCTR2000034780</p><p>ChiCTR2000039000</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated virus</td><td align="left" colspan="1" rowspan="1">BBIBP-CorV</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Beijing Institute of Biological Products/Sinopharm</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1"><p>Xia et al. (2020) [<xref ref-type="bibr" rid="CR156">156</xref>]</p><p>ChiCTR2000034780 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04560881">NCT04560881</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Recombinant new coronavirus vaccine (CHO cell)</td><td align="left" colspan="1" rowspan="1">Adjuvanted recombinant RBD-Dimer</td><td align="left" colspan="1" rowspan="1">Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences</td><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">CVnCoV</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Curevac</td><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04515147">NCT04515147</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">KBP-COVID-19</td><td align="left" colspan="1" rowspan="1">S protein RBD-based</td><td align="left" colspan="1" rowspan="1">Kentucky Bioprocessing, Inc</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04473690">NCT04473690</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 vaccine</td><td align="left" colspan="1" rowspan="1">Adjuvanted S protein</td><td align="left" colspan="1" rowspan="1">Sanofi Pasteur/GSK</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537208">NCT04537208</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">ARCT-021</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Arcturus/Duke-NUS</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">INO-4800</td><td align="left" colspan="1" rowspan="1">DNA plasmid with electroporation</td><td align="left" colspan="1" rowspan="1">Inovio Pharmaceuticals/International Vaccine Institute</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">AG0301-COVID19</td><td align="left" colspan="1" rowspan="1">Adjuvanted DNA plasmid</td><td align="left" colspan="1" rowspan="1">Osaka University/AnGes/Takara Bio</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04463472">NCT04463472</ext-link></p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527081">NCT04527081</ext-link></p></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">nCov Vaccine</td><td align="left" colspan="1" rowspan="1">DNA plasmid</td><td align="left" colspan="1" rowspan="1">Cadila Healthcare Limited</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1">CTRI/2020/07/026352</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">GX-19</td><td align="left" colspan="1" rowspan="1">DNA Vaccine</td><td align="left" colspan="1" rowspan="1">Genexine Consortium</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445389">NCT04445389</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1"><p>BBV152A</p><p>BBV152B</p><p>BBV152C</p></td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Bharat Biotech</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link></p><p>CTRI/2020/09/027674</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Inactivated SARS-CoV-2 Vaccine</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Institute of Medical Biology, Chinese Academy of Medical Sciences</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470609">NCT04470609</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">QazCovid-in</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Research Institute for Biological Safety Problems, Rep of Kazakhstan</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530357">NCT04530357</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VLP</td><td align="left" colspan="1" rowspan="1">RBD SARS-CoV-2 HBsAg VLP</td><td align="left" colspan="1" rowspan="1">RBD-HBsAg VLPs</td><td align="left" colspan="1" rowspan="1">SpyBiotech/Serum Institute of India</td><td align="left" colspan="1" rowspan="1">Phase I/II</td><td align="left" colspan="1" rowspan="1">ACTRN12620000817943</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">SCB-2019</td><td align="left" colspan="1" rowspan="1">Adjuvanted S protein</td><td align="left" colspan="1" rowspan="1">Clover Biopharmaceuticals Inc./GSK/Dynavax</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405908">NCT04405908</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">COVAX-19</td><td align="left" colspan="1" rowspan="1">S protein with Advax-SM adjuvant</td><td align="left" colspan="1" rowspan="1">Vaxine Pty Ltd/Medytox</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04453852">NCT04453852</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 Sclamp vaccine</td><td align="left" colspan="1" rowspan="1">Molecular clamp stabilized S protein with MF59 adjuvant</td><td align="left" colspan="1" rowspan="1">University of Queensland/CSL/Seqirus</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><p>ACTRN12620000674932p</p><p>ISRCTN51232965</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">MVC-COV1901</td><td align="left" colspan="1" rowspan="1">S-2P protein&#8201;+&#8201;CpG 1018</td><td align="left" colspan="1" rowspan="1">Medigen Vaccine Biologics Corporation/NIAID/Dynavax</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04487210">NCT04487210</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Soberana 01</td><td align="left" colspan="1" rowspan="1">S protein RBD with Adjuvant</td><td align="left" colspan="1" rowspan="1">Instituto Finlay de Vacunas, Cuba</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">IFV/COR/04</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">EpiVacCorona</td><td align="left" colspan="1" rowspan="1">Adjuvanted peptide antigen</td><td align="left" colspan="1" rowspan="1">FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Recombinant SARS-CoV-2 vaccine</td><td align="left" colspan="1" rowspan="1">S protein RBD (Sf9 cells)</td><td align="left" colspan="1" rowspan="1">West China Hospital, Sichuan University</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">ChiCTR2000037518</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">IMP (CoVac-1)</td><td align="left" colspan="1" rowspan="1">Multipeptide cocktail of SARS-CoV-2 HLA-DR peptides</td><td align="left" colspan="1" rowspan="1">University Hospital Tuebingen</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04546841">NCT04546841</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">UB-612</td><td align="left" colspan="1" rowspan="1">S1-RBD-protein</td><td align="left" colspan="1" rowspan="1">COVAXX</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04545749">NCT04545749</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">LNP-nCoVsaRNA</td><td align="left" colspan="1" rowspan="1">self-amplifying ribonucleic acid (saRNA) encoding S protein</td><td align="left" colspan="1" rowspan="1">Imperial College London</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">ISRCTN17072692</td></tr><tr><td align="left" colspan="1" rowspan="1">RNA</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2 mRNA vaccine</td><td align="left" colspan="1" rowspan="1">mRNA encoding S protein RBD</td><td align="left" colspan="1" rowspan="1">People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">ChiCTR2000034112</td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">hAd5-S-Fusion&#8201;+&#8201;N-ETSD vaccine</td><td align="left" colspan="1" rowspan="1">hAd5 Spike (S)&#8201;+&#8201;Nucleocapsid (N)</td><td align="left" colspan="1" rowspan="1">ImmunityBio, Inc. &amp; NantKwest Inc</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04591717">NCT04591717</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">GRAd-COV2</td><td align="left" colspan="1" rowspan="1">Replication defective Simian Adenovirus (GRAd)</td><td align="left" colspan="1" rowspan="1">ReiThera/LEUKOCARE/Univercells</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04528641">NCT04528641</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Ad5-nCoV</td><td align="left" colspan="1" rowspan="1">Ad5-based</td><td align="left" colspan="1" rowspan="1">CanSino Biological Inc/Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04552366">NCT04552366</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">VXA-CoV2-1</td><td align="left" colspan="1" rowspan="1">dsRNA-adjuvanted Ad5</td><td align="left" colspan="1" rowspan="1">Vaxart</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04563702">NCT04563702</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">MVA-SARS-2-S</td><td align="left" colspan="1" rowspan="1">MVA&#8201;+&#8201;spike protein (S)</td><td align="left" colspan="1" rowspan="1">Ludwig-Maximilians - University of Munich</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04569383">NCT04569383</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">V590</td><td align="left" colspan="1" rowspan="1">VSV&#8201;+&#8201;S protein</td><td align="left" colspan="1" rowspan="1">Merck Sharp &amp; Dohme/IAVI</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04569786">NCT04569786</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">TMV-083</td><td align="left" colspan="1" rowspan="1">Measles-vector based</td><td align="left" colspan="1" rowspan="1">Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp &amp; Dohme</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04497298">NCT04497298</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">DelNS1-2019-nCoV-RBD-OPT1</td><td align="left" colspan="1" rowspan="1">Intranasal flu-based-RBD</td><td align="left" colspan="1" rowspan="1">Beijing Wantai Biological Pharmacy/Xiamen University</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">ChiCTR2000037782</td></tr><tr><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">inactivated SARS-CoV-2 Vaccine</td><td align="left" colspan="1" rowspan="1">Inactivated</td><td align="left" colspan="1" rowspan="1">Beijing Minhai Biotechnology</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1">ChiCTR2000038804</td></tr><tr><td align="left" colspan="1" rowspan="1">VLP</td><td align="left" colspan="1" rowspan="1">Recombinant Coronavirus-Like Particle COVID 19 Vaccine</td><td align="left" colspan="1" rowspan="1">CpG 1018- or AS03-adjuvanted Plant-derived VLP</td><td align="left" colspan="1" rowspan="1">Medicago Inc</td><td align="left" colspan="1" rowspan="1">Phase I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04450004">NCT04450004</ext-link></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Protein subunit vaccine</title><p id="Par39">Protein subunit vaccines consist of viral antigenic fragments produced by recombinant protein techniques. They are easy to produce, and relatively safe and well-tolerated compared to whole virus vaccines and viral vector vaccines. The drawback of protein subunit vaccines is their low immunogenicity. Therefore, adjuvants and fusion with immunostimulatory molecules are usually used together with subunit vaccines to overcome this challenge.</p><p id="Par40">The development of SARS-CoV protein subunit vaccines was initially surrounding full-length S protein-based vaccines and then later focused on S protein RBD-based vaccines. None of the SARS-CoV protein subunit vaccines entered clinical trials, but they induced potent antibody responses and protective effects in preclinical models [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR44">44</xref>]. Studies have shown that full-length S protein, extracellular domain of the S protein, and trimeric S proteins (triSpike) are all immunogenic and can elicit protection against SARS-CoV infection [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. However, Kam et al. and Jamue et al. have found that triSpike vaccine can also cause Fc&#947; receptor II (Fc&#947;RII)-dependent SARS-CoV infection in human B cells in vitro [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. On the other hand, S protein RBD-based vaccines are able to induce high-titer neutralizing antibodies without causing obvious pathogenic effects [<xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR44">44</xref>]. This is probably because RBD-based vaccines do not contain additional non-neutralizing epitopes as full-length S protein vaccines do. One study has shown that RBD-based vaccines not only protect most of the SARS-CoV challenged mice with no detectable viral RNA in the lung, but can also induce long-lasting S-specific antibodies that can be maintained for 12&#160;months [<xref ref-type="bibr" rid="CR42">42</xref>]. Furthermore, RBD-based SARS-CoV vaccines have also been shown to induce RBD-specific IFN-&#947; producing cellular immune responses in mice [<xref ref-type="bibr" rid="CR44">44</xref>]. As a result, SARS-CoV RBD has become the main target for SARS vaccines. Finally, SARS-CoV subunit vaccines based on S2 subunit, N and M structural proteins have also been tested [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. However, no evidence has shown that they can induce neutralizing antibodies or protective effects against viral challenge.</p><p id="Par41">Guided by previous SARS-CoV experiences, most proteins subunit vaccines of MERS-CoV are focused on RBD-based vaccines. RBD-based MERS-CoV vaccines generally show great immunogenicity and elicit potent neutralizing antibodies, cell-mediated immunity, and protective effect against MERS-CoV infection [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. One study from Tai et al. found that trimeric RBD protein vaccines can induce long-lasting neutralizing antibodies for 6&#160;months [<xref ref-type="bibr" rid="CR26">26</xref>]. Another study also from Tai et al. demonstrated that recombinant RBD proteins from different MERS-CoV strains can induce antibodies that cross-neutralize with divergent human and camel MERS-CoV strains [<xref ref-type="bibr" rid="CR25">25</xref>]. These results indicate that MERS-CoV RBD serves as a promising vaccine target with the ability to induce long-lasting and broad-spectrum neutralizing antibodies against infection. Other than RBD-based vaccines, RBD-containing S1 subunit vaccines have also been shown to induce neutralizing antibodies and protection against MERS-CoV [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Notably, the N-terminal domain (NTD) of the S protein binds to sialic acid and is important for MERS-CoV infection in certain cell types. Jiaming et al. showed that immunization with NTD-based vaccine also provides protection against MERS-CoV and induces potent humoral and cell-mediated immunity [<xref ref-type="bibr" rid="CR49">49</xref>]. However, since SARS-CoV-2 NTD does not have the same sialic acid-binding function as MERS-CoV, NTD-based strategy might not be generalizable to SARS-CoV-2 vaccine development.</p><p id="Par42">Apart from antigen design, several other factors also affect the efficacy of protein subunit vaccines [<xref ref-type="bibr" rid="CR16">16</xref>]. The expression system of protein influences the quality and quantity of protein subunit vaccines. Du et al. demonstrated that SARS-CoV RBD protein expressed by mammalian 293T cells induces stronger neutralizing antibody responses than RBD expressed by insect cells and <italic toggle="yes">E. coli</italic>, which is probably due to the native conformation and post-translational modification maintained in mammalian cellular system [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition, adjuvants play an important role in enhancing the immunogenicity of protein subunit vaccines. Zhang et al. have examined multiple adjuvants (Freund&#8217;s, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59) in conjugation with MERS-CoV RBD and found that MF59 best potentiate the protein to elicit neutralizing antibodies and protective effects [<xref ref-type="bibr" rid="CR50">50</xref>]. Their data provide a good starting point for optimizing adjuvants for SARS-CoV-2 subunit vaccines. Moreover, the immunization route of the subunit vaccine can also affect its potency, and in combination with different antigen and adjuvants, the optimized vaccination pathway may change. For example, Li et al. demonstrated that for SARS-CoV S and S1 subunit vaccine, intramuscular (I.M.) route induces stronger antibody responses than subcutaneous (S.C.) route, while Lan et al. showed that S.C. route is preferable over I.M. injection for Freund&#8217;s and CpG-adjuvanted MERS-CoV RBD vaccine [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Therefore, the ideal route might need to be customized for SARS-CoV-2 subunit vaccines.</p></sec><sec id="Sec5"><title>Virus-like particle vaccine</title><p id="Par43">Virus-like particles (VLPs) are self-assembled viral structural proteins that mimic the conformation of native viruses but lack the viral genome. Compared with protein subunit vaccines, VLP vaccines present epitope in conformation that is more similar to the native virus, leading to better immunization responses. In addition, compared to whole virus vaccines, the production of VLP vaccines does not involve live virus or inactivation steps, which makes them safer vaccine candidates. The highly repetitive antigenic surface of VLP vaccines also help induce stronger antibody response by efficiently cross-linking B-cell surface receptors. Up to now, VLP vaccines have been commercialized for the protection against human papillomavirus (Cervarix&#8482; and Gardasil&#174;) and hepatitis B virus (Engerix&#174; and Recombivax HB&#174;) [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par44">Few SARS-CoV and MERS-CoV VLP vaccines have been reported so far. For SARS-CoV, Lokugamage et al. have demonstrated that chimeric VLPs composed of SARS-CoV S protein and mouse hepatitis virus E, M and N proteins can induce neutralizing antibody responses and reduce SARS-CoV virus titer in mice lung after viral challenge [<xref ref-type="bibr" rid="CR53">53</xref>]. In addition, another study performed by Liu et al. showed that chimeric VLPs consisting of SARS-CoV S protein and influenza virus M1 protein can induce neutralizing antibodies and provide protection against lethal challenge in mice [<xref ref-type="bibr" rid="CR54">54</xref>]. However, one study used the same chimeric VLPs as Lokugamage et al. and showed that this VLP vaccine can lead to pulmonary immunopathology on challenge with SARS-CoV [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Therefore, potential adverse effects of coronavirus VLP vaccines should be monitored. For MERS-CoV VLP vaccines, Wang et al. have shown that VLPs containing MERS-CoV S, E and M proteins can induce specific antibody response and Th1-mediated cellular immunity in rhesus macaques [<xref ref-type="bibr" rid="CR55">55</xref>]. The same research group developed another chimeric VLP vaccine containing the fusion of the receptor-binding domain (RBD) of MERS-CoV S protein and the canine parvovirus (CPV) VP2 structural protein [<xref ref-type="bibr" rid="CR56">56</xref>]. They showed that this VLP vaccine induces MERS-CoV-specific antibody response and T-cell immunity in mice [<xref ref-type="bibr" rid="CR56">56</xref>]. These studies suggested that VLP vaccines hold the potential for clinically effective coronavirus vaccines.</p></sec><sec id="Sec6"><title>DNA vaccine</title><p id="Par45">DNA vaccines contain genes encoding viral antigenic components that are expressed by plasmid vectors and delivered into cells through electroporation. Compared with other vaccine technologies, DNA vaccines offer a fast and flexible platform for vaccine development and production, making it an attractive technology to combat emerging epidemics like SARS-CoV-2. In addition, antigen production of DNA vaccines happens in the target cells, which helps recapitulate the native conformation and post-translational modification of viral antigens. However, an important drawback of DNA vaccines is their limited immunogenicity due to their inability to spread and amplify in vivo. Therefore, it is important to consider strategies that can enhance the potency of DNA vaccines, such as adding adjuvant or using a prime-boost regimen. Besides, the genomic integration of DNA vaccines into the host chromosome is another biosafety concern, which may lead to mutagenesis and oncogenesis [<xref ref-type="bibr" rid="CR57">57</xref>]. Even though previous studies have shown that the risk of vaccine plasmid insertion into the host chromosome is pretty low, the FDA and the WHO still recommends integration studies be included as part of the safety program of DNA vaccines [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par46">Several DNA vaccine candidates have been reported for SARS-CoV, including the S-, M-, and N protein-based vaccines [<xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR64">64</xref>]. Although all of them can generate a certain level of antibody and cell-immune responses, only S protein-based DNA vaccine has been shown to induce protective effect against SARS-CoV infection, probably due to the indispensable role of S protein in receptor binding [<xref ref-type="bibr" rid="CR60">60</xref>]. Yang et al. has demonstrated that immunization with DNA encoding full-length S protein, S protein lacking part of cytoplasmic domain, S protein lacking both cytoplasmic and transmembrane domains can all induce neutralizing antibodies and T-cell immune responses, as well as providing protective effect in mice [<xref ref-type="bibr" rid="CR60">60</xref>]. This promising result leads to a following phase I clinical trial based on SARS-CoV full-length S protein DNA vaccine, which showed that the vaccine was well-tolerated in patients and can induce neutralizing antibodies and T cell responses in healthy adults [<xref ref-type="bibr" rid="CR65">65</xref>]. Furthermore, two studies have made use of prime-boost strategy to enhance the potency of S protein-based SARS-CoV DNA vaccine. Zakhartchouk et al. reported that the combination of DNA and whole-inactivated SARS-CoV vaccines can increase the magnitude of antibody response as well as inducing a more desirable Th1-skewed immune response [<xref ref-type="bibr" rid="CR66">66</xref>]. Woo et al. demonstrated that using DNA vaccine priming plus <italic toggle="yes">E. coli</italic> expressed recombinant S protein booster can also induce higher neutralization titers than DNA or protein subunit vaccine alone [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par47">Similar to SARS-CoV, several studies on MERS-CoV DNA vaccines have demonstrated optimistic results. Muthumani et al. reported that a full-length S protein-based MERS-CoV DNA vaccine can induce potent cellular immunity and antigen-specific neutralizing antibodies in mice, macaques, and camels, and macaques vaccinated with this DNA vaccine were protected against MERS-CoV challenge without demonstrating any clinical or radiographic signs of pneumonia [<xref ref-type="bibr" rid="CR68">68</xref>]. Building on these encouraging data, a phase I clinical trial based on this MERS-CoV DNA vaccine (GLS-5300, or INO-4700) has been completed [<xref ref-type="bibr" rid="CR69">69</xref>]. The results showed that GLS-5300 is well tolerated with no vaccine-associated serious adverse events, and immunization with GLS-5300 induces durable immune responses in 85% of participants after two vaccinations [<xref ref-type="bibr" rid="CR69">69</xref>]. These data support further development of the GLS-5300 vaccine. Notably, a SARS-CoV-2 DNA vaccine candidate, INO-4800, is based on the same design as GLS-5300, and this vaccine is now in phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link>) [<xref ref-type="bibr" rid="CR70">70</xref>]. In addition, another MERS-CoV vaccine study using full-length S protein DNA priming plus S1 protein subunit booster elicits robust serum-neutralizing activity against several MERS-CoV strains in mice and rhesus macaques [<xref ref-type="bibr" rid="CR47">47</xref>]. Immunizing rhesus macaques with this DNA prime/protein boost vaccine confers protection against MERS-CoV-induced radiographic pneumonia, supporting this strategy as a promising approach for MERS-CoV vaccine development [<xref ref-type="bibr" rid="CR47">47</xref>]. Aside from full-length S, S1 subunit is also a good target for MERS-CoV DNA vaccine. One study performed by Al-Amri et al. has compared the immunogenicity of full-length S-based (pS) and S1-based (pS1) MERS-CoV vaccine using the same expression vector [<xref ref-type="bibr" rid="CR71">71</xref>]. They found that pS1 immunization elicited a balanced Th1/Th2 response and generally higher levels of all IgG isotypes compared to pS vaccination, which may be explained by the fact that the transmembrane domain-lacking S1 subunit is secreted more efficiently to the extracellular space and therefore result in greater uptake by antigen-presenting cells [<xref ref-type="bibr" rid="CR71">71</xref>]. This study suggested that S1 might be a better target than full-length S for MERS-CoV DNA vaccine [<xref ref-type="bibr" rid="CR71">71</xref>].</p><p id="Par48">Taken together, DNA vaccines encoding full-length S or S1 protein have demonstrated encouraging results to fight against SARS-CoV and MERS-CoV. The same strategy is likely to be generalizable to SARS-CoV-2 DNA vaccine considering the biological similarity.</p></sec><sec id="Sec7"><title>Viral vector vaccine</title><p id="Par49">Viral vector vaccines are recombinant viruses that encode antigens of interest in an unrelated modified virus. They deliver antigen into the cells mimicking natural infection, so they induce strong antigen-specific cellular and humoral immune responses per se, thereby obviating the need for additional adjuvants. In addition, viral vectors are able to accept large insertions in their genome, providing a flexible platform for antigen design. Despite these advantages, there are several drawbacks. The manufacturing process for viral vector vaccines is more complicated than other approaches, including the optimization of cellular systems and the exclusion of contaminants, which can greatly affect the efficiency of viral vectors [<xref ref-type="bibr" rid="CR57">57</xref>]. Moreover, recombinant viruses carry the risk of integrating their genome into the human host, so additional biosafety assessment will be required before entering clinical trials. Finally, if the chosen viral vector can infect the general populations, the pre-existing immunity on the viral vector could dampen the induced immune response, which has been seen in adenovirus- and measle virus-based vaccines [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par50">Similar to DNA and protein subunit vaccines, most viral vector coronavirus vaccines target the S antigen. Numerous viral vectors have been used to develop SARS-CoV and MERS-CoV vaccines, which have been described in detail in previous review articles [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. In the following sections, we will highlight vaccines based on adenovirus, modified vaccinia virus Ankara and Venezuelan equine encephalitis virus, which are the most well studied viral vector platforms for coronavirus vaccines. We will also briefly introduce other recombinant viral platforms that are being actively developed for coronavirus vaccines.</p><sec id="Sec8"><title>SARS-CoV viral vector vaccine</title><p id="Par51">Adenovirus is a popular viral vector vaccine that has been tested in clinical trials for a wide variety of diseases, and several studies have also examined the efficacy of adenovirus-based SARS-CoV vaccine. The feasibility of SARS adenovirus vector vaccine was first demonstrated in two study by Gao et al. and Liu et al. [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. They showed that adenoviral vector expressing S1 fragment can induce neutralizing antibodies in monkeys and rats, respectively, but neither studies showed evidences of in vivo protection against SARS-CoV challenge [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Later on, See et al. compared the efficacy of SARS-CoV S protein expressing adenovirus vaccine with the whole inactivated SARS-CoV vaccine [<xref ref-type="bibr" rid="CR78">78</xref>]. They found that both vaccines induce protective effects in mice against SARS-CoV challenge, though the neutralizing antibody response is weaker in adenovirus-based vaccine than whole-inactivated virus vaccine [<xref ref-type="bibr" rid="CR78">78</xref>]. Besides, Kobinger et al. have also tested a prime-boost regimen of S protein-expressing human adenovirus type 5 and chimpanzee derived adenoviruses in ferrets [<xref ref-type="bibr" rid="CR79">79</xref>]. Their results showed that this vaccine leads to a substantial reduction in viral load and prevents pneumonia in ferrets after SARS-CoV challenge [<xref ref-type="bibr" rid="CR79">79</xref>]. All these results have encouraged subsequent development of adenovirus-based MERS and COVID-19 vaccines.</p><p id="Par52">Modified vaccinia virus Ankara (MVA) is another well-established vaccine platform to combat emerging infectious diseases [<xref ref-type="bibr" rid="CR80">80</xref>]. Bisht et al. has shown that intranasal or intramuscular immunization with highly attenuated MVA containing full-length S gene induces both neutralizing antibody responses and protective immunity in mice, evident by reduced virus titer in mice lung post SARS-CoV challenge [<xref ref-type="bibr" rid="CR81">81</xref>]. Another study performed by Chen et al. demonstrated that recombinant MVA expressing SARS-CoV S protein elicits neutralizing antibodies in mice, ferrets, and monkeys, but they didn&#8217;t show any protection experiment data in this study [<xref ref-type="bibr" rid="CR82">82</xref>]. However, another two studies performed by Weingartl et al. and Czub et al. showed that MVA vaccine expressing SARS-CoV S protein does not provide protective effect in ferrets, and it even induces inflammatory responses and focal necrosis in the liver [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Therefore, potential adverse effects need to be considered for MVA-based SARS-CoV S protein vaccine.</p><p id="Par53">For Venezuelan equine encephalitis (VEE) virus-based SARS-CoV vaccine, Deming et al. has reported that VEE virus replicon particles (VRP) expressing S protein provides complete short- and long-term protection against homologous strain challenge in young and senescent mice [<xref ref-type="bibr" rid="CR85">85</xref>]. To further improve the efficacy of VEE virus-based vaccine against heterologous SARS-CoV challenge, Sheahan et al. has improved the immunogenicity of VRP S protein vaccine by substituting an attenuated VEE glycoprotein with its wild-type counterpart, and their result showed that the improved VRP S protein vaccine can protect aged mice from heterologous SARS-CoV challenge [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par54">Several additional viral vectors have also shown promising results for SARS-CoV vaccines. Two studies from Buchholz et al. and Bukreyev et al. have used an attenuated parainfluenza virus as vector to express SARS-CoV S protein, showing that parainfluenza-based vaccine can induce neutralizing antibody responses and protective effect against SARS-CoV challenge in hamsters and monkeys [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Besides, attenuated vesicular stomatitis virus (VSV) have also been tested as SARS-CoV vaccine vectors by Kapadia et al. [<xref ref-type="bibr" rid="CR88">88</xref>]. Their results showed that immunization with recombinant VSV expressing S protein can induce SARS-neutralizing antibodies and is able to protect mice from SARS-CoV infection [<xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec9"><title>MERS-CoV viral vector vaccine</title><p id="Par55">Several adenovirus-based MERS-CoV vaccines have been developed. Human adenovirus type 5 (Ad5) and type 41 (Ad41) expressing MERS-CoV S or S1 protein have been shown to induce neutralizing antibodies in mice [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. However, the protection effect of Ad5- and Ad41-based MERS vaccines have not been evaluated [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Notably, Ad5-MERS-S vaccine has been used in combination with S protein nanoparticles [<xref ref-type="bibr" rid="CR91">91</xref>]. Heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles has demonstrated not only protective effect in hDPP4-transduced mice against MERS-CoV challenge, but also more balanced Th1/Th2 responses than Ad5- or nanoparticles-alone homologous prime-boost vaccines [<xref ref-type="bibr" rid="CR91">91</xref>]. The Ad5 vector has already been applied to SARS-CoV-2 vaccine development, and promising results have been demonstrated in phase I and II clinical trials [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par56">Besides, chimpanzee adenovirus has been employed as viral vector with an aim to overcome the pre-existing immunity problem of human adenoviruses. A MERS-CoV S protein vaccine based on a chimpanzee adenoviral vector (ChAdOx1) was shown to induce high levels of neutralizing antibodies and cell-mediated immune in mice, and to protect hDPP4-transduced mice from lethal MERS-CoV challenge [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. In addition, ChAdOx1-MERS vaccine has also been demonstrated to reduce viral load in dromedary camels and provide protective immunity in rhesus macaques [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Given these promising preclinical results, the ChAdOx1-MERS vaccine has entered a phase I clinical trial, and the trial result showed that ChAdOx1-MERS was safe and well tolerated at all tested doses, and a single dose was capable of inducing both humoral and cellular responses against MERS-CoV [<xref ref-type="bibr" rid="CR98">98</xref>]. Notably, the same research team has applied ChAdOx1 platform to SARS-CoV-2 vaccine development and their product AZD1222 (or ChAdOx1-nCoV-19) is now a leading player of the COVID-19 vaccine race [<xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par57">The vaccine of modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV S protein has been reported to induce not only virus-neutralizing antibody responses and MERS-CoV-specific CD8+&#8201;T cell response, but also provide protective effect against MERS-CoV in DPP4-transduced mice [<xref ref-type="bibr" rid="CR100">100</xref>]. Furthermore, dromedary camels immunized with this MVA-based MERS-CoV S protein vaccine generate neutralizing antibodies and show less virus excretion after MERS-CoV infection [<xref ref-type="bibr" rid="CR101">101</xref>]. Since camel is a major animal reservoir for MERS-CoV, this vaccine provides an opportunity to effectively control camel-to-human transmission [<xref ref-type="bibr" rid="CR101">101</xref>]. Finally, a phase I clinical trial showed that MVA-MERS-S vaccine has a favorable safety profile, and homologous prime&#8211;boost immunization of MVA-MERS-S vaccine induces humoral and cell-mediated immune responses against MERS-CoV, which supports testing MVA-MERS-S vaccine in a larger population [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par58">MERS-CoV vaccines dependent on Venezuelan equine encephalitis (VEE) virus have also been studied. Agnihothram et al. have demonstrated that VEE virus replicon particles (VRP) expressing MERS-CoV S protein can induce neutralizing antibodies in young and aged mice [<xref ref-type="bibr" rid="CR103">103</xref>]. Another study from Zhao et al. found that VRP-based MERS N protein vaccine can induce memory CD4+&#8201;immune response and provide protective immunity against MERS-CoV in hDPP4-transduced mice [<xref ref-type="bibr" rid="CR28">28</xref>]. Since N protein is more conserved than S protein across different coronavirus species, their approach might hold the potential to develop a universal T cell-inducing coronavirus vaccine [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par59">Several other vaccine platforms have been applied for the development of MERS-CoV vaccine. Measle virus- and rabies virus-based MERS-CoV S protein vaccines have been shown to induce neutralizing antibodies and provide protective effect against MERS-CoV in hDDP4-transduced mice [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Newcastle disease virus and vesicular stomatitis virus vectors have also been employed as S protein-expressing MERS vaccines [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. However, only in vitro neutralization data have been provided and no in vivo protection data has been demonstrated for these two vaccines [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>].</p><p id="Par60">In summary, SARS-CoV and MERS-CoV vaccines based on many viral vectors, including adenovirus, modified vaccinia virus Ankara, Venezuelan equine encephalitis virus, parainfluenza virus, vesicular stomatitis virus, Measle virus, and rabies virus, have been shown to elicit protective immunity against viral challenges. Some of these viral vectors has already become promising candidate platforms for the development of SARS-CoV-2 vaccine.</p></sec></sec><sec id="Sec10"><title>Whole inactivated vaccine</title><p id="Par61">Whole inactivated vaccines are composed of chemically or radiationally inactivated virions. They contain a full repertoire of immunogenic components of the original virus, and compared with attenuated viruses, they carry no risk of viral reactivation if properly inactivated. Although safer than live attenuated vaccines, the immunogenic epitopes of inactivated viruses may be structurally deformed during the inactivation process, which can undermine the protection they may provide. Moreover, both SARS-CoV and MERS-CoV whole inactivated vaccines have been reported to induce eosinophil-related lung pathology [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. These disadvantages make whole inactivated vaccines a less attractive strategy for coronavirus vaccine development.</p><p id="Par62">During the early development of SARS-CoV vaccines, inactivated whole virus was once a leading strategy. Studies have shown that UV- and formaldehyde-inactivated SARS-CoV can induce neutralizing antibody response, and a phase I clinical trial using &#946;-propiolactone-inactivated SARS-CoV vaccine demonstrated that it is safe, well-tolerated, and can elicit SARS-CoV-specific neutralizing antibodies [<xref ref-type="bibr" rid="CR108">108</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>]. However, later studies found that a UV-formaldehyde doubly inactivated SARS-CoV vaccine, either unadjuvanted or alum-adjuvanted, provides incomplete protection in mice and induces eosinophilic pulmonary inflammatory response upon SARS-CoV challenge [<xref ref-type="bibr" rid="CR36">36</xref>]. Similarly, gamma-irradiated MERS-CoV vaccine adjuvanted with alum or MF59 also induces eosinophil-related lung pathology after virus challenge, despite its ability to induce neutralizing antibodies [<xref ref-type="bibr" rid="CR111">111</xref>]. These results have dampened the enthusiasm of whole-inactivated coronavirus vaccines. Nevertheless, recently two studies have revealed that UV-inactivated SARS-CoV adjuvanted with Toll-like receptor agonists, and formaldehyde-inactivated MERS-CoV adjuvanted with alum and unmethylated CpG, can reduce or even prevent Th2-skewed lung pathology after challenge [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. These results demonstrated that with an appropriate combination of inactivation method and adjuvants, the whole inactivated virus is still a viable option for coronavirus vaccine development.</p></sec><sec id="Sec11"><title>Live attenuated vaccine</title><p id="Par63">Live attenuated vaccines are live viruses weakened by deleting or mutating the pathogenic component of the viral genome. Similar to whole inactivated vaccines, they possess nearly the full immunogenic components of the original virus. Furthermore, they preserve the native conformation of viral antigens and present antigens to the immune system as in natural infections. Therefore, live attenuated vaccines are the most immunogenic kind of vaccine and have a long history of success in controlling a variety of infectious diseases [<xref ref-type="bibr" rid="CR113">113</xref>]. However, live attenuated vaccines also carry a higher risk than other types of vaccines, including the possibility of reversion to a virulent state and the danger of persistent infection in immunocompromised patients. Therefore, biosafety of live attenuated vaccines needs to be carefully evaluated before proceeding to clinical use.</p><p id="Par64">Although a few SARS-CoV and MERS-CoV live attenuated vaccines have demonstrated efficacy in animal models, none of them have proceeded to clinical trials [<xref ref-type="bibr" rid="CR114">114</xref>&#8211;<xref ref-type="bibr" rid="CR117">117</xref>]. The envelope (E) protein, besides its structural roles, has a major role in inflammasome activation and is associated with exacerbated inflammation in the lung [<xref ref-type="bibr" rid="CR118">118</xref>]. As a result, the deletion of E protein can lead to the decreased virulence of coronavirus [<xref ref-type="bibr" rid="CR119">119</xref>]. Lamirande et al. has reported that SARS-CoV mutants lacking the E gene can induce protective effects in hamsters against SARS-CoV challenge [<xref ref-type="bibr" rid="CR114">114</xref>]. In addition, nonstructural protein 16 (nsp16) is another viable target for the coronavirus vaccine. Nsp16 encodes ribose 2&#8242;-<italic toggle="yes">O</italic>-methyltransferase that is required for 5&#8242; capping of viral RNA [<xref ref-type="bibr" rid="CR120">120</xref>]. This methylation helps coronavirus avoid the activation of type I interferon-dependent innate immune response by viral RNA, and therefore nsp16 deletion attenuates virulence [<xref ref-type="bibr" rid="CR120">120</xref>]. Both SARS-CoV and MERS-CoV nsp16 mutant vaccines have been reported to provide protection against challenge [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. Moreover, nonstructural protein 14 (nsp14), which encodes exoribonuclease (ExoN) involved in RNA proofreading during replication, is also an useful target for live attenuated coronavirus vaccine [<xref ref-type="bibr" rid="CR121">121</xref>]. The loss of ExoN will cause a profound decrease in replication fidelity, and lead to attenuation of coronavirus pathogenesis [<xref ref-type="bibr" rid="CR121">121</xref>]. Graham et al. has shown that ExoN deletion can reduce SARS-CoV virulence in young, aged, immunocompromised mice, and ExoN-deleted SARS-CoV vaccine can induce a protective effect against challenge in these mice [<xref ref-type="bibr" rid="CR117">117</xref>]. In sum, all the targets mentioned above serve as potential strategies for the development of live attenuated SARS-CoV-2 vaccine.</p></sec><sec id="Sec12"><title>Recent progress on SARS-CoV-2 vaccine development</title><p id="Par65">Compared with SARS and MERS, which tended to resolve spontaneously after regional outbreak, the worldwide magnitude of the COVID-19 pandemic has made development of vaccine an unprecedented urgency. This urgent need has led to many different approaches in vaccine development considerations. First of all, unconventional vaccine platforms, such as nucleic acid vaccines and viral vector vaccines, are becoming the leading players in the race of COVID-19 vaccine development due to their ability to be developed using sequence information alone [<xref ref-type="bibr" rid="CR122">122</xref>]. These new platforms are therefore highly adaptable to emerging pathogens, and their safety profiles have already been well examined in recent influenza, Ebola and Zika outbreaks [<xref ref-type="bibr" rid="CR57">57</xref>]. Secondly, the clinical development process of COVID-19 vaccine has been accelerated by executing trials in parallel rather than following a linear sequence of steps. For example, multiple COVID-19 vaccine candidates directly entered clinical trials before having preclinical data in animal models, and many vaccine trials have adopted an integrated phase I/II or phase II/III approach to save time [<xref ref-type="bibr" rid="CR123">123</xref>]. Last but not least, in order to meet the massive global need of COVID-19 vaccine, vaccine developing companies, especially the front runners, are ramping up their manufacturing capacity to the scale of&#8201;~&#8201;1 billion doses per year [<xref ref-type="bibr" rid="CR124">124</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>]. Governments from the United States and several other countries are also playing an important role in funding the scale-up of potentially effective vaccines [<xref ref-type="bibr" rid="CR127">127</xref>&#8211;<xref ref-type="bibr" rid="CR129">129</xref>].</p><p id="Par66">In this section, we will discuss the latest preclinical and clinical development of COVID-19 vaccines (as of Oct 26, 2020). We will highlight representative COVID-19 vaccines from each major vaccine platform that have published clinical data (Table <xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec13"><title>Protein subunit vaccine</title><p id="Par67">Up to now, there have been 13 SARS-CoV-2 protein subunit vaccines entering clinical trials [<xref ref-type="bibr" rid="CR130">130</xref>]. Among these vaccines, a leading company Novavax, with its NVX-CoV2373 vaccine, has entered a phase IIb trial in South Africa (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link>) and a phase III trial in the UK (2020-004123-16). NVX-CoV2373 contains a prefusion stabilized full-length spike protein adjuvanted with their proprietary saponin-based adjuvant [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. In a preclinical trial, the vaccine induced neutralizing antibodies and prevented viral replication in the respiratory tract in macaques challenged with the virus [<xref ref-type="bibr" rid="CR131">131</xref>]. The vaccine also induced binding and neutralizing antibodies in all participants in the phase I trial [<xref ref-type="bibr" rid="CR132">132</xref>]. In their phase I trial, they also observed a dose sparing effect by the adjuvant. They found that both adjuvanted 5 ug and 25 ug dose regimens induced significantly high titers of neutralizing antibody compared to the placebo group and the 25 ug dose without adjuvant group [<xref ref-type="bibr" rid="CR132">132</xref>]. Another vaccine that has entered the phase II trial is Anhui Zhifei Longcom&#8217;s recombinant new coronavirus vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link>). Instead of using the full-length S protein, Anhui Zhifei Longcom&#8217;s vaccine only contains the RBD of the SARS-CoV-2 S protein. However, no further design or data has been provided so far. For the other candidate SARS-CoV-2 protein subunit vaccines, most of them also utilize either full-length S protein or the RBD of S protein as their vaccine antigen. Notably, one recent study has described a generalizable strategy to enhance the immunogenicity of protein subunit coronavirus vaccines [<xref ref-type="bibr" rid="CR133">133</xref>]. They identified a disulfide-linked dimeric form of MERS-RBD that is significantly more immunogenic and protective than its conventional monomeric counterpart [<xref ref-type="bibr" rid="CR133">133</xref>]. They applied the same strategy to SARS-CoV-2 and has demonstrated a 10&#8211;100-fold enhancement of neutralizing antibody titers [<xref ref-type="bibr" rid="CR133">133</xref>]. Therefore, this framework of immunogen design could be universally applicable to all protein subunit coronavirus vaccines in the future.</p></sec><sec id="Sec14"><title>DNA vaccine</title><p id="Par68">There are 4 DNA vaccines for SARS-CoV-2 currently under clinical trials [<xref ref-type="bibr" rid="CR130">130</xref>]. Among these developers, Inovio is a leading company that has published results on MERS-CoV and SARS-CoV-2 DNA vaccines. Inovio&#8217;s SARS-CoV-2 DNA vaccine INO-4800 encodes the full length S protein and is administered intradermally with a hand-held device CELLECTRA to electroporate the skin cell [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. Having experience in the phase I/IIa trial of their MERS vaccine (INO-4700), they are using the same platform for the SARS-CoV-2 vaccine INO-4800 [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. They have demonstrated that the vaccine induces neutralizing antibodies and Th1-skewed immune responses in animal models including mice, guinea pigs, and rhesus macaques [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. The vaccine is now in two phase I/II trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link>). The interim analysis of the two phase I trials showed it induced humoral and T cell immune responses in 94% participants after two doses while only caused adverse events of grade 1 or below [<xref ref-type="bibr" rid="CR136">136</xref>].</p></sec><sec id="Sec15"><title>RNA vaccine</title><p id="Par69">Although there were no RNA vaccine studies for SARS-CoV or MERS-CoV in the past two decades, there have already been 6 novel RNA vaccines reaching clinical trials for SARS-CoV-2 since the outbreak of COVID-19 [<xref ref-type="bibr" rid="CR130">130</xref>]. RNA vaccines consist of viral antigen-encoding messenger RNAs that can be translated by human cells to produce antigenic proteins and stimulate the immune system. RNA vaccines are usually delivered in complex with additional agents, such as protamine or lipid- and polymer-based nanoparticles, to increase its efficacy [<xref ref-type="bibr" rid="CR137">137</xref>]. Similar to DNA vaccines, RNA vaccines have the advantages of being highly adaptable to new pathogens and being able to recapitulate the native conformation and modifications of antigenic proteins. Furthermore, compared with DNA vaccines, RNA vaccines have some additional benefits. Unlike DNA, RNA does not interact with host-cell DNA and therefore obviate the risks of genomic integration. Besides, RNA vaccines can be given through multiple routes including traditional intravenous injection, whereas DNA vaccines need to be administered via special devices like electroporation or gene gun. Nevertheless, RNA vaccines do have some drawbacks. Exogenous RNA can activate interferon-mediated antiviral immune response and lead to stalled translation and mRNA degradation, which suppress the efficacy of RNA vaccines [<xref ref-type="bibr" rid="CR138">138</xref>]. In addition, interferon signaling is associated with inflammation and potential autoimmunity [<xref ref-type="bibr" rid="CR139">139</xref>]. Even though there have not been severe cases of RNA vaccine-induced autoimmune diseases, it is important to carefully evaluate this potential adverse effect.</p><p id="Par70">Moderna and BioNTech/Pfizer are the two leading developers for a SARS-CoV-2 RNA vaccine. Moderna's mRNA-1273 vaccine encodes a stabilized prefusion spike trimer, in which they substituted the amino acids at 986 and 987 with proline to stabilize the spike protein in its prefusion conformation [<xref ref-type="bibr" rid="CR140">140</xref>]. The nucleotides of the mRNA were also modified not only to increase its translation and half-life but also to prevent activation of interferon-associated genes upon entering the cell [<xref ref-type="bibr" rid="CR140">140</xref>].&#160;The preliminary report for their phase I clinical trial showed that: (1) neutralizing antibodies were detected in all 45 patients after two doses of immunization; (2) antibody titers of immunized patients were higher than convalescent serum after two doses of vaccination; (3) Th1-biased immune responses were observed in immunized patients [<xref ref-type="bibr" rid="CR140">140</xref>]. There were some cases of systemic adverse events after the second dose of vaccination, but no grade 4 adverse events were observed [<xref ref-type="bibr" rid="CR140">140</xref>]. They concluded that 100 ug can induce a satisfactory immune response and thus will continue to use 100 ug dosage in phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>) [<xref ref-type="bibr" rid="CR140">140</xref>]. In addition, they also expanded the same phase I trial to include 40 elderly participants with their age older than 55&#160;years old [<xref ref-type="bibr" rid="CR141">141</xref>]. Their result demonstrated that 100 ug dose of mRNA-1273 induced higher binding- and neutralizing-antibody titers than the 25 ug dose, and the adverse events associated with mRNA-1273 were mild or moderate in these elderly participants [<xref ref-type="bibr" rid="CR141">141</xref>].&#160;On Nov 16, 2020, Moderna revealed the&#160;first interim analysis of&#160;their phase III trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>)&#160;[<xref ref-type="bibr" rid="CR142">142</xref>].&#160;Their result showed that&#160;among 95 people who developed symptomatic COVID-19 after volunteering in this&#160;trial,&#160;only 5 of them were from the&#160;mRNA-1273 group, and the rest 90 cases were from the placebo group, resulting in a estimated vaccine efficacy of 94.5%&#160;[<xref ref-type="bibr" rid="CR142">142</xref>]. In addition, there were 11 volunteers who developed severe COVID-19 symptoms, and their analysis showed that all 11 cases were in the placebo group and none in the mRNA-1273 group&#160;[<xref ref-type="bibr" rid="CR142">142</xref>]. Their&#160;concurrent safety review also did not notice any significant safety concern&#160;[<xref ref-type="bibr" rid="CR142">142</xref>]. Therefore, their promising result suggested&#160;that the&#160;mRNA-1273 vaccine is safe and effective in preventing symptomatic COVID-19.&#160;</p><p id="Par71">BioNTech and Pfizer&#8217;s mRNA vaccine has four candidates, BNT162b1, BNT162b2, BNT162a1 and BNT162c2. BNT162b1 and BNT162b2 are both nucleoside modified mRNA (modRNA) vaccine [<xref ref-type="bibr" rid="CR143">143</xref>]. BNT162b1 encodes a trimerized RBD of spike protein while BNT162b2 encodes a full-length spike protein [<xref ref-type="bibr" rid="CR143">143</xref>]. On the other hand, BNT162a1 is a uridine mRNA (uRNA)-based vaccine and BNT162c2 is a self-amplifying mRNA (saRNA)-based vaccine [<xref ref-type="bibr" rid="CR143">143</xref>]. Up to now, BioNTech and Pfizer have published two BNT162b1 phase I/II trial results that were conducted in Germany&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link>) and the US&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>), respectively [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Both studies showed that the two-dose regimen of BNT162b1 elicited RBD-binding and neutralizing antibodies with titers above convalescent human serum [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Analysis of cell-mediated immune responses showed Th1-skewed response in most participants, as demonstrated by the detection of IFN&#947;, IL-2 and IL-12 but not IL-4 in their assay [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Although the German trial and the US trial used different dosages of vaccine, the two trials agreed with each other and showed that a regimen of 30&#8211;50 ug on day 1 and day 22 is able to elicit favorable immune response without severe adverse effects [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>].&#160;Following these two papers, they also published another study comparing the vaccination responses between BNT162b1 and BNT162b2 [<xref ref-type="bibr" rid="CR146">146</xref>]. BNT162b1 and BNT162b2 were shown to induce similar neutralizing titers in younger and older adults [<xref ref-type="bibr" rid="CR146">146</xref>]. However, BNT162b2 had less systemic reactogenicity in older adults [<xref ref-type="bibr" rid="CR146">146</xref>]. Therefore, they decided to move forward with BNT162b2 instead of BNT162b1 into a phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>).&#160;On Nov 18, 2020,&#160;Pfizer and BioNTech announced the efficacy analysis of their phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>) after meeting all primary efficacy endpoints&#160;[<xref ref-type="bibr" rid="CR147">147</xref>]. Their evaluation&#160;showed&#160;that&#160;BNT162b2 is 95% effective against COVID-19&#160;[<xref ref-type="bibr" rid="CR147">147</xref>]. This result was based on analyzing 170 confirmed COVID-19 cases, of which 162 cases of COVID-19 were observed in the placebo group while 8 cases in the&#160;BNT162b2 group&#160;[<xref ref-type="bibr" rid="CR147">147</xref>]. In addition, among 10 severe COVID-19 cases observed in this trial, 9 of them were in the placebo group and only 1 of them was in the&#160;BNT162b2 group&#160;[<xref ref-type="bibr" rid="CR147">147</xref>].&#160;Notably, the observed efficacy in the elderly people&#160;was over 94%, which would help protect the most vulnerable population against COVID-19&#160;[<xref ref-type="bibr" rid="CR147">147</xref>]. No serious safety concern was observed among 43,000 enrolled participants&#160;[<xref ref-type="bibr" rid="CR147">147</xref>]. These data indicated BNT162b2&#160;is another well-tolerated and&#160;efficacious COVID-19 vaccine.</p></sec><sec id="Sec16"><title>Viral vector vaccine</title><p id="Par72">Currently, there are 12 viral vector vaccines in clinical trials, and an additional 36 viral vector vaccines under preclinical development [<xref ref-type="bibr" rid="CR130">130</xref>]. Many viral vector platforms that have been tested in SARS-CoV and MERS-CoV are being explored in COVID-19 vaccines, including adenovirus (both human and non-human primates), measles virus, modified vaccinia virus Ankara (MVA), parainfluenza virus, rabies virus and vesicular stomatitis virus (VSV) [<xref ref-type="bibr" rid="CR130">130</xref>]. Surprisingly, Venezuelan equine encephalitis (VEE) virus, which has been extensively studied in SARS and MERS vaccine, hasn&#8217;t been tested in any COVID-19 vaccine studies yet. On the other hand, influenza virus vector, which hasn&#8217;t been explored for SARS and MERS viral vector vaccines, are now gaining popularity for the development of COVID-19 viral vector vaccine [<xref ref-type="bibr" rid="CR130">130</xref>]. For COVID-19 viral vector vaccines that have entered clinical trials, 8 out of 12 are based on adenoviruses, and the four leading candidates in this platform are AZD1222 (or ChAdOx1 nCoV-19, developed by Astrazeneca and Oxford University), Gam-COVID-Vac (or&#160;Sputnik V, or rAd26S+rAd5-S,&#160;developed by Gamaleya Research Institute), Ad5 (developed by CanSino Biological Inc. and Beijing Institute of Biotechnology),&#160;and Ad26 (developed by Johnson &amp; Johnson and Beth Israel Deaconess Medical Center) [<xref ref-type="bibr" rid="CR130">130</xref>].</p><p id="Par73">AZD1222 is a chimpanzee adenovirus-based viral vector vaccine (ChAdOx1) expressing SARS-CoV-2 spike protein [<xref ref-type="bibr" rid="CR99">99</xref>]. This ChAdOx1 platform has been used to develop MERS-CoV vaccine, which has demonstrated promising preclinical and phase I clinical trial data [<xref ref-type="bibr" rid="CR94">94</xref>&#8211;<xref ref-type="bibr" rid="CR98">98</xref>]. The AZD1222 vaccine team published their phase I/II trial interim report in July 2020 and showed that AZD1222 can elicit S protein-specific antibody and T-cell response and induce neutralizing antibody in all participants after the prime-boost regimen [<xref ref-type="bibr" rid="CR99">99</xref>]. No severe adverse effect has been observed [<xref ref-type="bibr" rid="CR99">99</xref>]. Based on this promising data, AZD1222 launched phase II/III trials in UK (2020-001228-32) and phase III trials in Brazil (ISRCTN89951424), United States (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link>), Russia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540393">NCT04540393</ext-link>) and India (CTRI/2020/08/027170). In Sep 2020, the AZD1222 phase II/III trial in the UK was once put on hold for safety review because a participant has developed unexplained illness, but following later independent review in the UK determined that the trial is still safe and therefore the AZD1222 clinical trial resumed [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>]. On Nov 23, 2020, Astrazeneca annouced&#160;the interim analysis of their&#160;clinical trial in UK (2020-001228-32) and Brazil (ISRCTN89951424)&#160;[<xref ref-type="bibr" rid="CR150">150</xref>]. Their pooled result showed that AZD1222&#160;has an average efficacy of 70%, based on analyzing&#160;a total of 131 COVID-19 cases from&#160;11,636 volunteers&#160;[<xref ref-type="bibr" rid="CR150">150</xref>].&#160;Interestingly, one dose regimen showed 90% efficacy when AZD1222 was given as half first dose&#160;followed by a full second dose (<italic toggle="yes">n</italic> = 2,741)&#160;[<xref ref-type="bibr" rid="CR150">150</xref>].&#160;On the other hand, two full dose regimen had&#160;only&#160;62% efficacy (<italic toggle="yes">n</italic> = 8,895)&#160;[<xref ref-type="bibr" rid="CR150">150</xref>]. Due to the response discrepancy between&#160;different subgroups, additional trials may be needed to better&#160;determine the efficacy and the most suitable regimen of AZD1222.&#160;In addition, the Gam-COVID-Vac vaccine team has published their phase I/II trial results [<xref ref-type="bibr" rid="CR151">151</xref>]. They conducted two different trials, with one using frozen formulation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436471">NCT04436471</ext-link>) and the other using lyophilized formulation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04437875">NCT04437875</ext-link>) of the vaccine [<xref ref-type="bibr" rid="CR151">151</xref>]. In both phase II trials, they tested their patients with heterologous prime-boost immunization of recombinant adenovirus type 26 vector encoding SARS-CoV-2 spike glycoprotein (rAd26-S) plus recombinant adenovirus type 5 vector encoding SARS-CoV-2 spike glycoprotein (rAd5-S) [<xref ref-type="bibr" rid="CR151">151</xref>]. Their results showed that both frozen and lyophilized formulation of the vaccine induced potent neutralizing antibodies and CD4+&#8201;and CD8+&#8201;T-cell immune responses, with the immune response of frozen formulation being slightly stronger than the lyophilized formulation [<xref ref-type="bibr" rid="CR151">151</xref>]. Both vaccines were safe and well-tolerated in all participants [<xref ref-type="bibr" rid="CR151">151</xref>]. Now this vaccine is also entering phase III trial in Russia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link>) and Belarus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04564716">NCT04564716</ext-link>).&#160;On Nov 24, 2020,&#160;Gamaleya Research Institute announced the second interim analysis of&#160;Gam-COVID-Vac (or&#160;Sputnik V) phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link>)&#160;[<xref ref-type="bibr" rid="CR152">152</xref>]. Their result showed that&#160;Gam-COVID-Vac had a efficacy of 91.4% on Day 28 after the first dose, which was&#160;based on analyzing&#160;39 confirmed cases among 18,794 volunteers&#160;[<xref ref-type="bibr" rid="CR152">152</xref>]. They also revealed&#160;that on&#160;Day 42 after the first dose (Day 21 after the second dose), the vaccine&#160;efficacy was even above 95%&#160;[<xref ref-type="bibr" rid="CR152">152</xref>]. There were no unexpected adverse effect documented during the trial&#160;[<xref ref-type="bibr" rid="CR152">152</xref>]. These promising results suggested that&#160;Gam-COVID-Vac is safe and effective in preventing COVID-19. Furthermore, the Ad5 vaccine team, whose vaccine is based on human adenovirus 5, has also published their clinical data&#160;[<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. In their phase II study, Ad5-vectored COVID-19 vaccine induces significant neutralizing antibodies and T-cell mediated immune response after single immunization&#160;[<xref ref-type="bibr" rid="CR93">93</xref>]. They tested two dosage, 1&#8201;&#215;&#8201;10<sup>11</sup> and 5&#8201;&#215;&#8201;10<sup>10</sup> viral particles, and showed that the 5&#8201;&#215;&#8201;10<sup>10</sup> dose causes less severe adverse reactions without compromising the immunogenicity [<xref ref-type="bibr" rid="CR93">93</xref>]. Now this vaccine has advance to two phase III global multi-centered clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526990">NCT04526990</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04540419">NCT04540419</ext-link>).&#160;Finally, Johnson &amp; Johnson&#8217;s Ad26-based COVID-19 vaccine has also entered phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link>), but no data from its earlier trial has been reported yet.</p></sec><sec id="Sec17"><title>Whole inactivated vaccine</title><p id="Par74">Currently, there are 7 whole inactivated COVID-19 vaccine in clinical trials [<xref ref-type="bibr" rid="CR130">130</xref>]. From the previous experience of SARS-CoV and MERS-CoV vaccine development, whole inactivated virus can induce adverse effect such as eosinophil-related lung immunopathology in preclinical models [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Even though no serious adverse effect has been reported for whole-inactivated COVID-19 vaccine, it is important for the research community to keep this in mind and carefully evaluate potential adverse effects. For all ongoing trials of whole inactivated COVID-19 vaccine, three of them have publicly reported their preclinical or clinical data. SinoVac Inc. developed CoronaVac (also known as PiCoVacc), which is a beta-propiolactone inactivated, Vero cell line propagated whole virus vaccine originated from a patient-derived CN-2 SARS-CoV-2 virus strain [<xref ref-type="bibr" rid="CR153">153</xref>]. In their preclinical study, PiCoVacc induces broad neutralizing antibodies against 10 representative SARS-CoV-2 strains in mice, rats, and non-human primates [<xref ref-type="bibr" rid="CR153">153</xref>]. Immunizing macaques with three doses of PiCoVacc provides them with protective immunity against SARS-CoV-2 challenge without causing any antibody-dependent enhancement effect [<xref ref-type="bibr" rid="CR153">153</xref>]. Following their preclinical study, CoronaVac has completed two phase I/II trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>, result not yet published) and is now starting phase III clinical trial in Brazil (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link>), Indonesia (669/UN6.KEP/EC/2020) and Turkey (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04582344">NCT04582344</ext-link>). In addition, Sinopharm Inc. and Wuhan Institute of Biological Products have developed a different COVID-19 inactivated virus vaccine (no specific product name). In this vaccine, WIV04 strain was isolated from a COVID-19 patient in Wuhan, propagated in Vero cells, and followed by two rounds of beta-propiolactone inactivation [<xref ref-type="bibr" rid="CR154">154</xref>]. They tested three different dosage and three different injection timelines in their phase I and phase II studies, and their phase I/II interim report showed that patients receiving different vaccination regimen all had demonstrated neutralizing antibodies and with only a low rate of adverse reactions [<xref ref-type="bibr" rid="CR154">154</xref>]. Now they have launched a phase III clinical trial in United Arab Emirates (ChiCTR2000034780) and Kuwait (ChiCTR2000039000). Finally, Sinopharm Inc. also collaborated with Beijing Institute of Biological Products to develop another COVID-19 inactivated virus vaccine BBIBP-CorV [<xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. The manufacturing process of BBIBP-CorV is very similar to the other vaccine Sinopharm Inc. produced, except that BBIBP-CorV used a different HB02 strain rather than WIV04 strain [<xref ref-type="bibr" rid="CR155">155</xref>]. They have tested BBIBP-CorV in preclinical models and showed that two-dose immunization of BBIBP-CorV can protect rhesus macaques from SARS-CoV-2 challenge [<xref ref-type="bibr" rid="CR155">155</xref>]. Following this, they completed a clinical phase I/II trial with BBIBP-CorV and demonstrated that BBIBP-CorV is safe and well-tolerated in all tested doses in two age groups [<xref ref-type="bibr" rid="CR156">156</xref>]. Furthermore, their immunogenicity result showed that humoral responses against SARS-CoV-2 were induced in all vaccine recipients 42&#160;days after immunization [<xref ref-type="bibr" rid="CR156">156</xref>]. Now this vaccine is under phase III clinical trial in United Arab Emirates (ChiCTR2000034780) and Argentina (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04560881">NCT04560881</ext-link>).</p></sec><sec id="Sec18"><title>Other vaccine platforms</title><p id="Par75">There are also several other COVID-19 vaccine candidates using different technologies other than the platforms mentioned above. Virus-like particle-based vaccine, which has been demonstrated to induce humoral and cell-mediated immunity in SARS-CoV and MERS-CoV preclinical models, has one candidate COVID-19 vaccine in phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04450004">NCT04450004</ext-link>) and 14 vaccine candidates under preclinical development [<xref ref-type="bibr" rid="CR130">130</xref>]. However, none of the group has publicly reported their vaccine studies yet. Live attenuated vaccine, which has been shown to provide protective effect in SARS-CoV and MERS-CoV challenged mice, has 3 preclinical ongoing studies [<xref ref-type="bibr" rid="CR130">130</xref>]. The higher risk of adverse effect has made live attenuated vaccine a less appealing choice for the time-sensitive race of COVID-19 vaccine development. Nevertheless, if successfully developed, live attenuated vaccine can provide the most potent protective effect due to its high similarity to natural infection.</p><p id="Par76">In addition to these traditional platforms, scientists have also developed COVID-19 vaccines using unconventional approaches. Aivita Biomedical, Inc. has developed AV-COVID-19, which is an autologous dendritic cells vaccine loaded with SARS-CoV-2 antigens [<xref ref-type="bibr" rid="CR157">157</xref>]. AV-COVID-19 is derived from patients&#8217; own peripheral blood monocytes, then differentiated in vitro into dendritic cells, and incubated with SARS-CoV-2 antigens before injecting back into patients&#8217; blood [<xref ref-type="bibr" rid="CR157">157</xref>]. Now the company has launched a phase I/II clinical trial to evaluate its safety and efficacy profile in adults (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04386252">NCT04386252</ext-link>). Besides, Symvivo Corporation has developed bacTRL-Spike, a live Bifidobacterium vaccine engineered to deliver synthetic plasmid DNA encoding spike protein from SARS-CoV-2. They have also registered a phase I clinical trial to examine the safety of this vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04334980">NCT04334980</ext-link>). Moreover, a group from Nanjing University has found that a plant microRNA, MIR2911, can target SARS-CoV-2 by binding to their mRNA and blocking protein translation [<xref ref-type="bibr" rid="CR158">158</xref>]. Their data showed that MIR2911 inhibited SARS-CoV-2 replication and accelerated negative conversion of infected patients [<xref ref-type="bibr" rid="CR158">158</xref>]. Following their study, they are now launching a phase I clinical trial (ChiCTR2000031432) in China to evaluate the safety and tolerance of MIR2911 in patients.</p><p id="Par77">Finally, people have been testing existing licensed vaccines and trying to repurpose them to combat COVID-19. It has been shown that tuberculosis vaccine bacillus Calmette&#8211;Gu&#233;rin (BCG) can train innate immunity and induce nonspecific host defensive reaction against viral pathogens, including respiratory syncytial virus (RSV), influenza A virus and herpes simplex virus type 2 (HSV2) [<xref ref-type="bibr" rid="CR159">159</xref>&#8211;<xref ref-type="bibr" rid="CR162">162</xref>]. Additionally, an interesting study compared the national difference in COVID-19 impact and correlated it with national BCG vaccination policy [<xref ref-type="bibr" rid="CR163">163</xref>]. They found that countries without universal policies of BCG vaccination have been more severely affected compared to countries with universal and long-standing BCG policies [<xref ref-type="bibr" rid="CR163">163</xref>]. Based on these rationales, there have been at least 13 phase III clinical trials testing whether BCG vaccine can reduce the morbidity and mortality of healthcare workers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04328441">NCT04328441</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04327206">NCT04327206</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04350931">NCT04350931</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348370">NCT04348370</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04362124">NCT04362124</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04369794">NCT04369794</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04373291">NCT04373291</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04379336">NCT04379336</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04384549">NCT04384549</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04439045">NCT04439045</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04387409">NCT04387409</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04417335">NCT04417335</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04414267">NCT04414267</ext-link>).</p></sec><sec id="Sec19"><title>Additional considerations for SARS-CoV-2 vaccine development</title><p id="Par78">Given the rapid transmission and asymptomatic spread of COVID-19, it is clear that an effective vaccine with global immunization coverage is required to bring people&#8217;s lives back to normalcy. However, even when an effective SARS-CoV-2 vaccine becomes available, the duration of vaccine-induced immunity is still largely unknown. Previous SARS studies have shown that SARS-specific IgG and neutralizing antibodies were only maintained for approximately 2&#160;years in patients who recovered from SARS-CoV infection [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]. As a result, permanent immunity is less likely to be the case for COVID-19 vaccines, and a regular vaccination policy might be required in the future. In addition, it is still unclear what is the minimal neutralizing antibody titer that can provide protective effect against SARS-CoV-2 infection. It is believed that the higher neutralizing antibody vaccination induces, the better protective effect it will be. This is consistent with the observation that most COVID-19 reinfection cases only experience mild or no symptom during their first infection, which might not be sufficient to induce strong neutralizing antibodies [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. Therefore, it is of great importance that further studies characterize the correlation between neutralizing antibody and protective effect to guide COVID-19 vaccine development. Last but not least, various mutations have been detected in the SARS-CoV-2 genome, with D614G mutation being the most prevalent one [<xref ref-type="bibr" rid="CR168">168</xref>]. D614G is a missense point mutation in S protein that increases the infectivity of SARS-CoV-2 by decreasing S1 shedding and increasing S protein incorporation into virion [<xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR170">170</xref>]. Fortunately, D614G mutation does not prevent neutralizing antibodies from binding to SARS-CoV-2 and thus does not provide resistance to vaccination [<xref ref-type="bibr" rid="CR170">170</xref>]. However, it is possible that such immune-escaping mutations appears in the future and makes COVID-19 vaccine development even more difficult.</p></sec><sec id="Sec20"><title>Concluding remarks</title><p id="Par79">Since the discovery of human coronaviruses in 1960s, new types of coronaviruses have kept emerging and have gradually become a serious threat to global public health. Even though there have been almost two decades since the first coronavirus outbreak, the scientific and medical community are not well prepared with effective weapons to combat these pathogens. One lesson we learned from this is that the financial and regulatory mechanism of current pharmaceutical market does not provide enough incentive to encourage vaccine development before a deadly outbreak happens. To make up for this, now academic institutions and companies all over the world are developing an explosive numbers of vaccine candidates with highly compressed clinical trial schedules. Fortunately, the biological and clinical lessons we learned from SARS-CoV and MERS-CoV researches, together with the vaccine development experience we gained from other diseases, have already guided us to come up with multiple promising candidate solutions. Besides, multiple therapeutic candidates targeting molecules in SARS-CoV-2 life cycle and human immune response against COVID-19 have also been rapidly explored, with Remdesivir and Dexamethasone being the two leading drugs that showed promising clinical evidences in shortening the time to recovery and decreasing mortality rates [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]. These treatment options can be complementary to SARS-CoV-2 vaccines to achieve overall mitigation of the COVID-19 pandemic. In conclusion, we hope countries all over the world, regardless of political ideologies, can unite and work together to achieve fast and successful COVID-19 vaccine development in the near future.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>COVID-19</term><def><p id="Par2">Coronavirus Disease 2019</p></def></def-item><def-item><term>CoV</term><def><p id="Par3">Coronavirus</p></def></def-item><def-item><term>SARS-CoV</term><def><p id="Par4">Severe Acute Respiratory Syndrome Coronavirus</p></def></def-item><def-item><term>MERS-CoV</term><def><p id="Par5">Middle East Respiratory Syndrome Coronavirus</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p id="Par6">Severe Acute Respiratory Syndrome Coronavirus 2</p></def></def-item><def-item><term>pp</term><def><p id="Par7">Polyproteins</p></def></def-item><def-item><term>Nsps</term><def><p id="Par8">Non-structural proteins</p></def></def-item><def-item><term>S</term><def><p id="Par9">Spike</p></def></def-item><def-item><term>E</term><def><p id="Par10">Envelope</p></def></def-item><def-item><term>M</term><def><p id="Par11">Membrane</p></def></def-item><def-item><term>N</term><def><p id="Par12">Necleocapsid</p></def></def-item><def-item><term>RBD</term><def><p id="Par13">Receptor binding domain</p></def></def-item><def-item><term>ACE2</term><def><p id="Par14">Angiotensin-converting enzyme 2</p></def></def-item><def-item><term>DPP4</term><def><p id="Par15">Dipeptidyl peptidase-4</p></def></def-item><def-item><term>ER</term><def><p id="Par16">Endoplasmic reticulum</p></def></def-item><def-item><term>ADE</term><def><p id="Par17">Antibody-dependent enhancement</p></def></def-item><def-item><term>NTD</term><def><p id="Par18">N-terminal domain</p></def></def-item><def-item><term>IM</term><def><p id="Par19">Intramuscular</p></def></def-item><def-item><term>SC</term><def><p id="Par20">Subcutaneous</p></def></def-item><def-item><term>VLP</term><def><p id="Par21">Virus-like particle</p></def></def-item><def-item><term>CPV</term><def><p id="Par22">Canine parvovirus</p></def></def-item><def-item><term>VEE</term><def><p id="Par23">Venezuelan equine encephalitis</p></def></def-item><def-item><term>VRP</term><def><p id="Par24">Virus replicon particle</p></def></def-item><def-item><term>Ad#</term><def><p id="Par25">Human adenovirus type #</p></def></def-item><def-item><term>ChAdOx1</term><def><p id="Par26">Chimpanzee Adenoviral Vector</p></def></def-item><def-item><term>ExoN</term><def><p id="Par27">Exoribonuclease</p></def></def-item><def-item><term>modRNA</term><def><p id="Par28">Modified RNA</p></def></def-item><def-item><term>uRNA</term><def><p id="Par29">Uridine mRNA</p></def></def-item><def-item><term>saRNA</term><def><p id="Par30">Self-amplifying RNA</p></def></def-item><def-item><term>RSV</term><def><p id="Par31">Respiratory synctial virus</p></def></def-item><def-item><term>HSV</term><def><p id="Par32">Herpes simplex virus</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yen-Der Li and Wei-Yu Chi have contributed equally to this work</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>YDL and WYC contributed to the conception of the manuscript and to the original draft preparation. JHS, LF, and CFH contributed to substantial review and preparation of the manuscript. TCW supervised the review. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par80">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par81">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par82">Dr T.C. Wu is a co-founder of and has an equity ownership interest in Papivax LLC. Additionally Dr. Wu owns Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.&#8217;s Scientific Advisory Board. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Centers-for-Disease-Control-and-Prevention. Human Coronavirus Types. 2020.&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/types.html">https://www.cdc.gov/coronavirus/types.html</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Hoek</surname><given-names>L</given-names></name></person-group><article-title>Human coronaviruses: what do they cause?</article-title><source>Antivir Ther</source><year>2007</year><volume>12</volume><issue>4 Pt B</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17944272</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World-Health-Organization</collab></person-group><source>Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003</source><year>2003</year><publisher-loc>Geneva</publisher-loc><publisher-name>World-Health-Organization</publisher-name></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World-Health-Organization</collab></person-group><source>MERS situation update, January 2020</source><year>2020</year><publisher-loc>Geneva</publisher-loc><publisher-name>World-Health-Organization</publisher-name></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Rio</surname><given-names>C</given-names></name><name name-style="western"><surname>Collins</surname><given-names>LF</given-names></name><name name-style="western"><surname>Malani</surname><given-names>P</given-names></name></person-group><article-title>Long-term health consequences of COVID-19</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.19719</pub-id><pub-id pub-id-type="pmid">33031513</pub-id><pub-id pub-id-type="pmcid">PMC8019677</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>R</given-names></name><name name-style="western"><surname>Leung</surname><given-names>KSM</given-names></name><name name-style="western"><surname>Lau</surname><given-names>EHY</given-names></name><name name-style="western"><surname>Wong</surname><given-names>JY</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Tu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shao</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TTY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Leung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>13</issue><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmid">31995857</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>M</given-names></name><name name-style="western"><surname>Yokoe</surname><given-names>DS</given-names></name><name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name></person-group><article-title>Asymptomatic transmission, the Achilles' Heel of current strategies to control covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>22</issue><fpage>2158</fpage><lpage>2160</lpage><pub-id pub-id-type="doi">10.1056/NEJMe2009758</pub-id><pub-id pub-id-type="pmid">32329972</pub-id><pub-id pub-id-type="pmcid">PMC7200054</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World-Health-Organization</collab></person-group><source>Coronavirus disease (COVID-19) pandemic</source><year>2020</year><publisher-loc>Geneva</publisher-loc><publisher-name>World-Health-Organization</publisher-name></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masters</surname><given-names>PS</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source>Adv Virus Res</source><year>2006</year><volume>66</volume><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id><pub-id pub-id-type="pmid">16877062</pub-id><pub-id pub-id-type="pmcid">PMC7112330</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stadler</surname><given-names>K</given-names></name><name name-style="western"><surname>Masignani</surname><given-names>V</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Abrignani</surname><given-names>S</given-names></name><name name-style="western"><surname>Klenk</surname><given-names>HD</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><article-title>SARS&#8211;beginning to understand a new virus</article-title><source>Nat Rev Microbiol</source><year>2003</year><volume>1</volume><issue>3</issue><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nrmicro775</pub-id><pub-id pub-id-type="pmid">15035025</pub-id><pub-id pub-id-type="pmcid">PMC7097337</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></name><name name-style="western"><surname>Zuniga</surname><given-names>S</given-names></name><name name-style="western"><surname>Castano-Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>J</given-names></name><name name-style="western"><surname>Canton</surname><given-names>J</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I</given-names></name></person-group><article-title>Molecular Basis of Coronavirus Virulence and Vaccine Development</article-title><source>Adv Virus Res</source><year>2016</year><volume>96</volume><fpage>245</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.003</pub-id><pub-id pub-id-type="pmid">27712626</pub-id><pub-id pub-id-type="pmcid">PMC7112271</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">NCBI-Reference-Sequence. SARS coronavirus Tor2, complete genome. 2020.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">NCBI-Reference-Sequence. Middle East respiratory syndrome-related coronavirus isolate HCoV-EMC/2012, complete genome. 2020.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">NCBI-Reference-Sequence. Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. 2020.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>The spike protein of SARS-CoV&#8211;a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><year>2009</year><volume>7</volume><issue>3</issue><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmid">19198616</pub-id><pub-id pub-id-type="pmcid">PMC2750777</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source>Front Microbiol</source><year>2020</year><volume>11</volume><fpage>298</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.00298</pub-id><pub-id pub-id-type="pmid">32265848</pub-id><pub-id pub-id-type="pmcid">PMC7105881</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snijder</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Decroly</surname><given-names>E</given-names></name><name name-style="western"><surname>Ziebuhr</surname><given-names>J</given-names></name></person-group><article-title>The nonstructural proteins directing coronavirus RNA synthesis and processing</article-title><source>Adv Virus Res</source><year>2016</year><volume>96</volume><fpage>59</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.008</pub-id><pub-id pub-id-type="pmid">27712628</pub-id><pub-id pub-id-type="pmcid">PMC7112286</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients</article-title><source>Virol J</source><year>2010</year><volume>7</volume><fpage>299</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-7-299</pub-id><pub-id pub-id-type="pmid">21047436</pub-id><pub-id pub-id-type="pmcid">PMC2988023</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>ZF</given-names></name><name name-style="western"><surname>Sin</surname><given-names>WY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Mak</surname><given-names>CK</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>CS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TY</given-names></name><name name-style="western"><surname>Lai</surname><given-names>ST</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name></person-group><article-title>B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>6</issue><fpage>3401</fpage><lpage>3408</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.6.3401-3408.2005</pub-id><pub-id pub-id-type="pmid">15731234</pub-id><pub-id pub-id-type="pmcid">PMC1075701</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>M</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Dai</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Si</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name></person-group><article-title>Antibody responses to individual proteins of SARS coronavirus and their neutralization activities</article-title><source>Microbes Infect</source><year>2005</year><volume>7</volume><issue>5&#8211;6</issue><fpage>882</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.02.006</pub-id><pub-id pub-id-type="pmid">15878679</pub-id><pub-id pub-id-type="pmcid">PMC7110836</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>XC</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>SS</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stanhope</surname><given-names>J</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>EC</given-names></name><name name-style="western"><surname>Avnir</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tallarico</surname><given-names>AS</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name><name name-style="western"><surname>Marasco</surname><given-names>WA</given-names></name></person-group><article-title>Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><issue>19</issue><fpage>E2018</fpage><lpage>2026</lpage><pub-id pub-id-type="doi">10.1073/pnas.1402074111</pub-id><pub-id pub-id-type="pmid">24778221</pub-id><pub-id pub-id-type="pmcid">PMC4024880</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name></person-group><article-title>A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein</article-title><source>Cell Res</source><year>2015</year><volume>25</volume><issue>11</issue><fpage>1237</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.113</pub-id><pub-id pub-id-type="pmid">26391698</pub-id><pub-id pub-id-type="pmcid">PMC4650419</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ulitzky</surname><given-names>L</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>E</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>DR</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R</given-names></name></person-group><article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title><source>Viral Immunol</source><year>2013</year><volume>26</volume><issue>2</issue><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1089/vim.2012.0076</pub-id><pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Heck</surname><given-names>S</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design</article-title><source>J Virol</source><year>2006</year><volume>80</volume><issue>12</issue><fpage>5757</fpage><lpage>5767</lpage><pub-id pub-id-type="doi">10.1128/JVI.00083-06</pub-id><pub-id pub-id-type="pmid">16731915</pub-id><pub-id pub-id-type="pmcid">PMC1472569</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fett</surname><given-names>CA</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants</article-title><source>J Virol</source><year>2017</year><pub-id pub-id-type="doi">10.1128/JVI.01651-16</pub-id><pub-id pub-id-type="pmid">27795425</pub-id><pub-id pub-id-type="pmcid">PMC5165220</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CK</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><year>2016</year><volume>499</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CK</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><issue>7</issue><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmid">28277821</pub-id><pub-id pub-id-type="pmcid">PMC5512770</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Mangalam</surname><given-names>AK</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name><name name-style="western"><surname>David</surname><given-names>CS</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses</article-title><source>Immunity</source><year>2016</year><volume>44</volume><issue>6</issue><fpage>1379</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id><pub-id pub-id-type="pmid">27287409</pub-id><pub-id pub-id-type="pmcid">PMC4917442</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>P</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus</article-title><source>J Clin Microbiol</source><year>2005</year><volume>43</volume><issue>8</issue><fpage>3718</fpage><lpage>3726</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.8.3718-3726.2005</pub-id><pub-id pub-id-type="pmid">16081901</pub-id><pub-id pub-id-type="pmcid">PMC1234014</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>UJ</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Collins</surname><given-names>PL</given-names></name></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><issue>26</issue><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403492101</pub-id><pub-id pub-id-type="pmid">15210961</pub-id><pub-id pub-id-type="pmcid">PMC470755</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huisman</surname><given-names>W</given-names></name><name name-style="western"><surname>Martina</surname><given-names>BE</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name name-style="western"><surname>Gruters</surname><given-names>RA</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>Vaccine-induced enhancement of viral infections</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>4</issue><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.087</pub-id><pub-id pub-id-type="pmid">19022319</pub-id><pub-id pub-id-type="pmcid">PMC7131326</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>YW</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>YC</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Chu</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tse</surname><given-names>J</given-names></name><name name-style="western"><surname>Guarner</surname><given-names>J</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>SR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>M</given-names></name><name name-style="western"><surname>Nal</surname><given-names>B</given-names></name><name name-style="western"><surname>Altmeyer</surname><given-names>R</given-names></name></person-group><article-title>Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>4</issue><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.011</pub-id><pub-id pub-id-type="pmid">17049691</pub-id><pub-id pub-id-type="pmcid">PMC7115629</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaume</surname><given-names>M</given-names></name><name name-style="western"><surname>Yip</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>CY</given-names></name><name name-style="western"><surname>Leung</surname><given-names>HL</given-names></name><name name-style="western"><surname>Li</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F</given-names></name><name name-style="western"><surname>Dutry</surname><given-names>I</given-names></name><name name-style="western"><surname>Callendret</surname><given-names>B</given-names></name><name name-style="western"><surname>Escriou</surname><given-names>N</given-names></name><name name-style="western"><surname>Altmeyer</surname><given-names>R</given-names></name><name name-style="western"><surname>Nal</surname><given-names>B</given-names></name><name name-style="western"><surname>Daeron</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruzzone</surname><given-names>R</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>JS</given-names></name></person-group><article-title>Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>20</issue><fpage>10582</fpage><lpage>10597</lpage><pub-id pub-id-type="doi">10.1128/JVI.00671-11</pub-id><pub-id pub-id-type="pmid">21775467</pub-id><pub-id pub-id-type="pmcid">PMC3187504</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>SP</given-names></name><name name-style="western"><surname>Yen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>CH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>FT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>WT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JC</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>451</volume><issue>2</issue><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.090</pub-id><pub-id pub-id-type="pmid">25073113</pub-id><pub-id pub-id-type="pmcid">PMC7092860</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>KS</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>DH</given-names></name></person-group><article-title>Vaccines: all things considered</article-title><source>Clin Vaccine Immunol</source><year>2006</year><volume>13</volume><issue>8</issue><fpage>821</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1128/CVI.00152-06</pub-id><pub-id pub-id-type="pmid">16893980</pub-id><pub-id pub-id-type="pmcid">PMC1539119</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D</given-names></name><name name-style="western"><surname>Long</surname><given-names>K</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L</given-names></name><name name-style="western"><surname>Totura</surname><given-names>A</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>23</issue><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></name><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Newman</surname><given-names>PC</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Atmar</surname><given-names>RL</given-names></name><name name-style="western"><surname>Peters</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Couch</surname><given-names>RB</given-names></name></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>4</issue><fpage>e35421</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmid">22536382</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Uda</surname><given-names>A</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Sata</surname><given-names>T</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>N</given-names></name></person-group><article-title>Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title><source>J Virol</source><year>2014</year><volume>88</volume><issue>15</issue><fpage>8597</fpage><lpage>8614</lpage><pub-id pub-id-type="doi">10.1128/JVI.00983-14</pub-id><pub-id pub-id-type="pmid">24850731</pub-id><pub-id pub-id-type="pmcid">PMC4135953</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D</given-names></name><name name-style="western"><surname>Ong</surname><given-names>CH</given-names></name><name name-style="western"><surname>Peng</surname><given-names>BH</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group><article-title>Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>6</issue><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1128/JVI.02980-14</pub-id><pub-id pub-id-type="pmid">25520500</pub-id><pub-id pub-id-type="pmcid">PMC4337527</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>324</volume><issue>2</issue><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.106</pub-id><pub-id pub-id-type="pmid">15474494</pub-id><pub-id pub-id-type="pmcid">PMC7092904</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>384</volume><issue>4</issue><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.05.003</pub-id><pub-id pub-id-type="pmid">19422787</pub-id><pub-id pub-id-type="pmcid">PMC2750803</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>15</issue><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.031</pub-id><pub-id pub-id-type="pmid">17092615</pub-id><pub-id pub-id-type="pmcid">PMC7115660</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and <italic toggle="yes">E. coli</italic> cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><year>2009</year><volume>393</volume><issue>1</issue><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.07.018</pub-id><pub-id pub-id-type="pmid">19683779</pub-id><pub-id pub-id-type="pmcid">PMC2753736</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity</article-title><source>Viral Immunol</source><year>2010</year><volume>23</volume><issue>2</issue><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1089/vim.2009.0090</pub-id><pub-id pub-id-type="pmid">20374001</pub-id><pub-id pub-id-type="pmcid">PMC2883479</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus</article-title><source>DNA Cell Biol</source><year>2005</year><volume>24</volume><issue>8</issue><fpage>510</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1089/dna.2005.24.510</pub-id><pub-id pub-id-type="pmid">16101349</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Leng</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lien</surname><given-names>SP</given-names></name><name name-style="western"><surname>Chi</surname><given-names>HY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lian</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>SL</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P</given-names></name></person-group><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>16</issue><fpage>3100</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.058</pub-id><pub-id pub-id-type="pmid">16494977</pub-id><pub-id pub-id-type="pmcid">PMC7115648</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K</given-names></name><name name-style="western"><surname>Lees</surname><given-names>CR</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Becker</surname><given-names>MM</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Olinger</surname><given-names>G</given-names></name><name name-style="western"><surname>Todd</surname><given-names>JP</given-names></name><name name-style="western"><surname>Bagci</surname><given-names>U</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>J</given-names></name><name name-style="western"><surname>Mollura</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P</given-names></name><name name-style="western"><surname>Denison</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>SS</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>PD</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>7712</fpage><pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adney</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MR</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>3</issue><fpage>212</fpage><pub-id pub-id-type="doi">10.3390/v11030212</pub-id><pub-id pub-id-type="pmid">30832356</pub-id><pub-id pub-id-type="pmcid">PMC6466352</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B</given-names></name><name name-style="western"><surname>Baoying</surname><given-names>H</given-names></name><name name-style="western"><surname>Jinghua</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wenjie</surname><given-names>T</given-names></name></person-group><article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>1</issue><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Tasneem</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell Mol Immunol</source><year>2016</year><volume>13</volume><issue>2</issue><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>e112602</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name></person-group><article-title>Recent progress on the versatility of virus-like particles</article-title><source>Vaccines (Basel)</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>139</fpage><pub-id pub-id-type="doi">10.3390/vaccines8010139</pub-id><pub-id pub-id-type="pmcid">PMC7157238</pub-id><pub-id pub-id-type="pmid">32244935</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>KG</given-names></name><name name-style="western"><surname>Yoshikawa-Iwata</surname><given-names>N</given-names></name><name name-style="western"><surname>Ito</surname><given-names>N</given-names></name><name name-style="western"><surname>Watts</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wyde</surname><given-names>PR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Newman</surname><given-names>P</given-names></name><name name-style="western"><surname>Kent Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Peters</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S</given-names></name></person-group><article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>6</issue><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.092</pub-id><pub-id pub-id-type="pmid">18191004</pub-id><pub-id pub-id-type="pmcid">PMC2267761</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YV</given-names></name><name name-style="western"><surname>Massare</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>DL</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name></person-group><article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>38</issue><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.111</pub-id><pub-id pub-id-type="pmid">21762752</pub-id><pub-id pub-id-type="pmcid">PMC3165014</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>8</issue><fpage>12686</fpage><lpage>12694</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8475</pub-id><pub-id pub-id-type="pmid">27050368</pub-id><pub-id pub-id-type="pmcid">PMC5355045</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antiviral Res</source><year>2017</year><volume>140</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>S</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>KE</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1963</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmid">30283434</pub-id><pub-id pub-id-type="pmcid">PMC6156540</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Troilo</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>TG</given-names></name><name name-style="western"><surname>Pacchione</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Barnum</surname><given-names>AB</given-names></name><name name-style="western"><surname>Harper</surname><given-names>LB</given-names></name><name name-style="western"><surname>Pauley</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Denisova</surname><given-names>L</given-names></name><name name-style="western"><surname>Follmer</surname><given-names>TT</given-names></name><name name-style="western"><surname>Rizzuto</surname><given-names>G</given-names></name><name name-style="western"><surname>Ciliberto</surname><given-names>G</given-names></name><name name-style="western"><surname>Fattori</surname><given-names>E</given-names></name><name name-style="western"><surname>Monica</surname><given-names>NL</given-names></name><name name-style="western"><surname>Manam</surname><given-names>S</given-names></name><name name-style="western"><surname>Ledwith</surname><given-names>BJ</given-names></name></person-group><article-title>Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation</article-title><source>Gene Ther</source><year>2004</year><volume>11</volume><issue>8</issue><fpage>711</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302213</pub-id><pub-id pub-id-type="pmid">14724672</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schalk</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mooi</surname><given-names>FR</given-names></name><name name-style="western"><surname>Berbers</surname><given-names>GA</given-names></name><name name-style="western"><surname>van Aerts</surname><given-names>LA</given-names></name><name name-style="western"><surname>Ovelgonne</surname><given-names>H</given-names></name><name name-style="western"><surname>Kimman</surname><given-names>TG</given-names></name></person-group><article-title>Preclinical and clinical safety studies on DNA vaccines</article-title><source>Hum Vaccin</source><year>2006</year><volume>2</volume><issue>2</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.4161/hv.2.2.2620</pub-id><pub-id pub-id-type="pmid">17012886</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Kong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title><source>Nature</source><year>2004</year><volume>428</volume><issue>6982</issue><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/nature02463</pub-id><pub-id pub-id-type="pmid">15024391</pub-id><pub-id pub-id-type="pmcid">PMC7095382</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CF</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MC</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>YC</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>TC</given-names></name></person-group><article-title>Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>9</issue><fpage>4638</fpage><lpage>4645</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.9.4638-4645.2004</pub-id><pub-id pub-id-type="pmid">15078946</pub-id><pub-id pub-id-type="pmcid">PMC387705</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Qin</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Ke</surname><given-names>JS</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JG</given-names></name><name name-style="western"><surname>Qi</surname><given-names>ZT</given-names></name></person-group><article-title>Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine</article-title><source>Virology</source><year>2005</year><volume>331</volume><issue>1</issue><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2004.10.016</pub-id><pub-id pub-id-type="pmid">15582659</pub-id><pub-id pub-id-type="pmcid">PMC7111813</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Kita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kanamaru</surname><given-names>N</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tsunai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakatani</surname><given-names>H</given-names></name><name name-style="western"><surname>Fukamizu</surname><given-names>R</given-names></name><name name-style="western"><surname>Namie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>J</given-names></name><name name-style="western"><surname>Takao</surname><given-names>K</given-names></name><name name-style="western"><surname>Asai</surname><given-names>R</given-names></name><name name-style="western"><surname>Asaki</surname><given-names>R</given-names></name><name name-style="western"><surname>Kase</surname><given-names>T</given-names></name><name name-style="western"><surname>Takemoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>T</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>I</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakatani</surname><given-names>M</given-names></name></person-group><article-title>Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>16</issue><fpage>3038</fpage><lpage>3040</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.032</pub-id><pub-id pub-id-type="pmid">17289225</pub-id><pub-id pub-id-type="pmcid">PMC7115525</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Hengge</surname><given-names>UR</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YF</given-names></name></person-group><article-title>Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>327</volume><issue>1</issue><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.11.147</pub-id><pub-id pub-id-type="pmid">15629440</pub-id><pub-id pub-id-type="pmcid">PMC7092945</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>JE</given-names></name><name name-style="western"><surname>Louder</surname><given-names>MK</given-names></name><name name-style="western"><surname>Holman</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Enama</surname><given-names>ME</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>BD</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>CA</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Koup</surname><given-names>RA</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M</given-names></name><name name-style="western"><surname>Bailer</surname><given-names>RT</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>PL</given-names></name><name name-style="western"><surname>Nason</surname><given-names>M</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Team</surname><given-names>VRCS</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><issue>50</issue><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmid">18824060</pub-id><pub-id pub-id-type="pmcid">PMC2612543</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakhartchouk</surname><given-names>AN</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>LA</given-names></name></person-group><article-title>Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>35</issue><fpage>4385</fpage><lpage>4391</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.04.011</pub-id><pub-id pub-id-type="pmid">16005746</pub-id><pub-id pub-id-type="pmcid">PMC7115501</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>PC</given-names></name><name name-style="western"><surname>Lau</surname><given-names>SK</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>HW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>LP</given-names></name><name name-style="western"><surname>He</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from <italic toggle="yes">Escherichia coli</italic> as booster induces high titer of neutralizing antibody against SARS coronavirus</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>42</issue><fpage>4959</fpage><lpage>4968</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.05.023</pub-id><pub-id pub-id-type="pmid">15993989</pub-id><pub-id pub-id-type="pmcid">PMC7115571</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K</given-names></name><name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C</given-names></name><name name-style="western"><surname>Flingai</surname><given-names>S</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>DO</given-names></name><name name-style="western"><surname>Wise</surname><given-names>M</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Izmirly</surname><given-names>A</given-names></name><name name-style="western"><surname>Aljuaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Seliga</surname><given-names>AM</given-names></name><name name-style="western"><surname>Soule</surname><given-names>G</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>M</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>KA</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AS</given-names></name><name name-style="western"><surname>Scott</surname><given-names>DP</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name><name name-style="western"><surname>LaCasse</surname><given-names>R</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>K</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A</given-names></name><name name-style="western"><surname>Ugen</surname><given-names>KE</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>NY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kobinger</surname><given-names>G</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates</article-title><source>Sci Transl Med</source><year>2015</year><volume>7</volume><issue>301</issue><fpage>301ra132</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aac7462</pub-id><pub-id pub-id-type="pmid">26290414</pub-id><pub-id pub-id-type="pmcid">PMC4573558</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>CC</given-names></name><name name-style="western"><surname>Mills</surname><given-names>KT</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>AR</given-names></name><name name-style="western"><surname>Paolino</surname><given-names>K</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Racine</surname><given-names>T</given-names></name><name name-style="western"><surname>Oh</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lamarre</surname><given-names>C</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>FI</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J</given-names></name><name name-style="western"><surname>Kudchodkar</surname><given-names>SB</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>M</given-names></name><name name-style="western"><surname>Darden</surname><given-names>JM</given-names></name><name name-style="western"><surname>Park</surname><given-names>YK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PT</given-names></name><name name-style="western"><surname>Remigio</surname><given-names>C</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wise</surname><given-names>MC</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Duperret</surname><given-names>EK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name><name name-style="western"><surname>White</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagarazzi</surname><given-names>M</given-names></name><name name-style="western"><surname>May</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kane</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobinger</surname><given-names>G</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NL</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>JN</given-names></name></person-group><article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>9</issue><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30266-X</pub-id><pub-id pub-id-type="pmid">31351922</pub-id><pub-id pub-id-type="pmcid">PMC7185789</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TRF</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Gary</surname><given-names>EN</given-names></name><name name-style="western"><surname>Walker</surname><given-names>SN</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K</given-names></name><name name-style="western"><surname>Purwar</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Walters</surname><given-names>J</given-names></name><name name-style="western"><surname>Bhojnagarwala</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chokkalingam</surname><given-names>N</given-names></name><name name-style="western"><surname>Pezzoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Parzych</surname><given-names>E</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Doan</surname><given-names>A</given-names></name><name name-style="western"><surname>Tursi</surname><given-names>N</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>M</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Tello-Ruiz</surname><given-names>E</given-names></name><name name-style="western"><surname>Maricic</surname><given-names>I</given-names></name><name name-style="western"><surname>Bah</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Amante</surname><given-names>D</given-names></name><name name-style="western"><surname>Park</surname><given-names>DH</given-names></name><name name-style="western"><surname>Dia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AR</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>FI</given-names></name><name name-style="western"><surname>Generotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KY</given-names></name><name name-style="western"><surname>Herring</surname><given-names>TA</given-names></name><name name-style="western"><surname>Reeder</surname><given-names>S</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>VM</given-names></name><name name-style="western"><surname>Buttigieg</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JM</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AS</given-names></name><name name-style="western"><surname>Khoshnejad</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>MW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Humeau</surname><given-names>L</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>KE</given-names></name></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>2601</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Amri</surname><given-names>SS</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>AT</given-names></name><name name-style="western"><surname>Siddiq</surname><given-names>LA</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanki</surname><given-names>MA</given-names></name><name name-style="western"><surname>Al-Muhanna</surname><given-names>MK</given-names></name><name name-style="western"><surname>Alhabbab</surname><given-names>RY</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>EI</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Hashem</surname><given-names>AM</given-names></name></person-group><article-title>Immunogenicity of Candidate MERS-CoV DNA vaccines based on the spike protein</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>44875</fpage><pub-id pub-id-type="doi">10.1038/srep44875</pub-id><pub-id pub-id-type="pmid">28332568</pub-id><pub-id pub-id-type="pmcid">PMC5362948</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fausther-Bovendo</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group><article-title>Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?</article-title><source>Hum Vaccin Immunother</source><year>2014</year><volume>10</volume><issue>10</issue><fpage>2875</fpage><lpage>2884</lpage><pub-id pub-id-type="doi">10.4161/hv.29594</pub-id><pub-id pub-id-type="pmid">25483662</pub-id><pub-id pub-id-type="pmcid">PMC5443060</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knuchel</surname><given-names>MC</given-names></name><name name-style="western"><surname>Marty</surname><given-names>RR</given-names></name><name name-style="western"><surname>Morin</surname><given-names>TN</given-names></name><name name-style="western"><surname>Ilter</surname><given-names>O</given-names></name><name name-style="western"><surname>Zuniga</surname><given-names>A</given-names></name><name name-style="western"><surname>Naim</surname><given-names>HY</given-names></name></person-group><article-title>Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector</article-title><source>Hum Vacc Immunother</source><year>2013</year><volume>9</volume><issue>3</issue><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.4161/hv.23241</pub-id><pub-id pub-id-type="pmcid">PMC3891717</pub-id><pub-id pub-id-type="pmid">23324399</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></name><name name-style="western"><surname>Dediego</surname><given-names>ML</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>E</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R</given-names></name></person-group><article-title>Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease</article-title><source>Virus Res</source><year>2008</year><volume>133</volume><issue>1</issue><fpage>45</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2007.01.021</pub-id><pub-id pub-id-type="pmid">17416434</pub-id><pub-id pub-id-type="pmcid">PMC2633062</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindewolf</surname><given-names>C</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name></person-group><article-title>Middle East respiratory syndrome vaccine candidates: cautious optimism</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>1</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.3390/v11010074</pub-id><pub-id pub-id-type="pmcid">PMC6356267</pub-id><pub-id pub-id-type="pmid">30658390</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A</given-names></name><name name-style="western"><surname>Soloff</surname><given-names>A</given-names></name><name name-style="western"><surname>D'Aiuto</surname><given-names>L</given-names></name><name name-style="western"><surname>Nwanegbo</surname><given-names>E</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>PD</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Barratt-Boyes</surname><given-names>S</given-names></name><name name-style="western"><surname>Gambotto</surname><given-names>A</given-names></name></person-group><article-title>Effects of a SARS-associated coronavirus vaccine in monkeys</article-title><source>Lancet</source><year>2003</year><volume>362</volume><issue>9399</issue><fpage>1895</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14962-8</pub-id><pub-id pub-id-type="pmid">14667748</pub-id><pub-id pub-id-type="pmcid">PMC7112457</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>RY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ke</surname><given-names>ML</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JM</given-names></name><name name-style="western"><surname>Tan</surname><given-names>WP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HK</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>YX</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats</article-title><source>Virus Res</source><year>2005</year><volume>112</volume><issue>1&#8211;2</issue><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2005.02.009</pub-id><pub-id pub-id-type="pmid">16022898</pub-id><pub-id pub-id-type="pmcid">PMC7114075</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>See</surname><given-names>RH</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Mok</surname><given-names>CPY</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T</given-names></name><name name-style="western"><surname>Zitzow</surname><given-names>LA</given-names></name><name name-style="western"><surname>Karunakaran</surname><given-names>KP</given-names></name><name name-style="western"><surname>Voss</surname><given-names>TG</given-names></name><name name-style="western"><surname>Brunham</surname><given-names>RC</given-names></name><name name-style="western"><surname>Gauldie</surname><given-names>J</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></name><name name-style="western"><surname>Roper</surname><given-names>RL</given-names></name></person-group><article-title>Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines</article-title><source>J Gen Virol</source><year>2008</year><volume>89</volume><issue>Pt 9</issue><fpage>2136</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/001891-0</pub-id><pub-id pub-id-type="pmid">18753223</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name><name name-style="western"><surname>Figueredo</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sanmiguel</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bell</surname><given-names>P</given-names></name><name name-style="western"><surname>Wivel</surname><given-names>NA</given-names></name><name name-style="western"><surname>Zitzow</surname><given-names>LA</given-names></name><name name-style="western"><surname>Flieder</surname><given-names>DB</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JM</given-names></name></person-group><article-title>Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>28</issue><fpage>5220</fpage><lpage>5231</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.065</pub-id><pub-id pub-id-type="pmid">17559989</pub-id><pub-id pub-id-type="pmcid">PMC7115643</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G</given-names></name></person-group><article-title>Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development</article-title><source>Adv Virus Res</source><year>2017</year><volume>97</volume><fpage>187</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.07.001</pub-id><pub-id pub-id-type="pmid">28057259</pub-id><pub-id pub-id-type="pmcid">PMC7112317</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisht</surname><given-names>H</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Collins</surname><given-names>PL</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><issue>17</issue><fpage>6641</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401939101</pub-id><pub-id pub-id-type="pmid">15096611</pub-id><pub-id pub-id-type="pmcid">PMC404098</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Ba</surname><given-names>L</given-names></name><name name-style="western"><surname>Yi</surname><given-names>CE</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Tu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gettie</surname><given-names>A</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>5</issue><fpage>2678</fpage><lpage>2688</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.5.2678-2688.2005</pub-id><pub-id pub-id-type="pmid">15708987</pub-id><pub-id pub-id-type="pmcid">PMC548443</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czub</surname><given-names>M</given-names></name><name name-style="western"><surname>Weingartl</surname><given-names>H</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>R</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>17&#8211;18</issue><fpage>2273</fpage><lpage>2279</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.033</pub-id><pub-id pub-id-type="pmid">15755610</pub-id><pub-id pub-id-type="pmcid">PMC7115540</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weingartl</surname><given-names>H</given-names></name><name name-style="western"><surname>Czub</surname><given-names>M</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>J</given-names></name><name name-style="western"><surname>Marszal</surname><given-names>P</given-names></name><name name-style="western"><surname>Gren</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S</given-names></name><name name-style="western"><surname>Proulx</surname><given-names>R</given-names></name><name name-style="western"><surname>Deschambault</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grudeski</surname><given-names>E</given-names></name><name name-style="western"><surname>Andonov</surname><given-names>A</given-names></name><name name-style="western"><surname>He</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Copps</surname><given-names>J</given-names></name><name name-style="western"><surname>Grolla</surname><given-names>A</given-names></name><name name-style="western"><surname>Dick</surname><given-names>D</given-names></name><name name-style="western"><surname>Berry</surname><given-names>J</given-names></name><name name-style="western"><surname>Ganske</surname><given-names>S</given-names></name><name name-style="western"><surname>Manning</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name></person-group><article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>22</issue><fpage>12672</fpage><lpage>12676</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.22.12672-12676.2004</pub-id><pub-id pub-id-type="pmid">15507655</pub-id><pub-id pub-id-type="pmcid">PMC525089</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deming</surname><given-names>D</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B</given-names></name><name name-style="western"><surname>Davis</surname><given-names>N</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A</given-names></name><name name-style="western"><surname>Suthar</surname><given-names>M</given-names></name><name name-style="western"><surname>Harkema</surname><given-names>J</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name><name name-style="western"><surname>Pickles</surname><given-names>R</given-names></name><name name-style="western"><surname>West</surname><given-names>A</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R</given-names></name></person-group><article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><issue>12</issue><fpage>e525</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030525</pub-id><pub-id pub-id-type="pmid">17194199</pub-id><pub-id pub-id-type="pmcid">PMC1716185</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name><name name-style="western"><surname>Long</surname><given-names>K</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M</given-names></name><name name-style="western"><surname>Rockx</surname><given-names>B</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M</given-names></name><name name-style="western"><surname>Davis</surname><given-names>N</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>1</issue><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1128/JVI.01805-10</pub-id><pub-id pub-id-type="pmid">20980507</pub-id><pub-id pub-id-type="pmcid">PMC3014161</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bukreyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>UJ</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>LN</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>WR</given-names></name><name name-style="western"><surname>St Claire</surname><given-names>M</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Collins</surname><given-names>PL</given-names></name></person-group><article-title>Mucosal immunisation of African green monkeys (<italic toggle="yes">Cercopithecus aethiops</italic>) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9427</issue><fpage>2122</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16501-X</pub-id><pub-id pub-id-type="pmid">15220033</pub-id><pub-id pub-id-type="pmcid">PMC7112367</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapadia</surname><given-names>SU</given-names></name><name name-style="western"><surname>Rose</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name></person-group><article-title>Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine</article-title><source>Virology</source><year>2005</year><volume>340</volume><issue>2</issue><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.06.016</pub-id><pub-id pub-id-type="pmid">16043204</pub-id><pub-id pub-id-type="pmcid">PMC7111745</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K</given-names></name><name name-style="western"><surname>Kenniston</surname><given-names>T</given-names></name><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name><name name-style="western"><surname>AlHajri</surname><given-names>MM</given-names></name><name name-style="western"><surname>Farag</surname><given-names>EA</given-names></name><name name-style="western"><surname>AlHajri</surname><given-names>F</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name><name name-style="western"><surname>Gambotto</surname><given-names>A</given-names></name></person-group><article-title>Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>45</issue><fpage>5975</fpage><lpage>5982</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.058</pub-id><pub-id pub-id-type="pmid">25192975</pub-id><pub-id pub-id-type="pmcid">PMC7115510</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X</given-names></name><name name-style="western"><surname>Hung</surname><given-names>T</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus</article-title><source>Immunology</source><year>2015</year><volume>145</volume><issue>4</issue><fpage>476</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1111/imm.12462</pub-id><pub-id pub-id-type="pmid">25762305</pub-id><pub-id pub-id-type="pmcid">PMC4515128</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kang</surname><given-names>KW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EY</given-names></name><name name-style="western"><surname>Seo</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>T</given-names></name><name name-style="western"><surname>Park</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SM</given-names></name><name name-style="western"><surname>Nam</surname><given-names>JH</given-names></name></person-group><article-title>Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><issue>24</issue><fpage>3468</fpage><lpage>3476</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.082</pub-id><pub-id pub-id-type="pmid">29739720</pub-id><pub-id pub-id-type="pmcid">PMC7115429</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JX</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>BS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>HD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gou</surname><given-names>JB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>SB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XW</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10240</issue><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name><name name-style="western"><surname>Li</surname><given-names>JX</given-names></name><name name-style="western"><surname>Yang</surname><given-names>BF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>XH</given-names></name><name name-style="western"><surname>Xu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jia</surname><given-names>SY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>BS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>XA</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>HX</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>HD</given-names></name><name name-style="western"><surname>Deng</surname><given-names>P</given-names></name><name name-style="western"><surname>Gou</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XW</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10249</issue><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alharbi</surname><given-names>NK</given-names></name><name name-style="western"><surname>Padron-Regalado</surname><given-names>E</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>CP</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Grehan</surname><given-names>K</given-names></name><name name-style="western"><surname>Temperton</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Warimwe</surname><given-names>G</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AVS</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><issue>30</issue><fpage>3780</fpage><lpage>3788</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.032</pub-id><pub-id pub-id-type="pmid">28579232</pub-id><pub-id pub-id-type="pmcid">PMC5516308</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Wells</surname><given-names>D</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></name><name name-style="western"><surname>Saturday</surname><given-names>G</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name><name name-style="western"><surname>Warimwe</surname><given-names>GM</given-names></name></person-group><article-title>Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0029-1</pub-id><pub-id pub-id-type="pmid">29263883</pub-id><pub-id pub-id-type="pmcid">PMC5643297</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alharbi</surname><given-names>NK</given-names></name><name name-style="western"><surname>Qasim</surname><given-names>I</given-names></name><name name-style="western"><surname>Almasoud</surname><given-names>A</given-names></name><name name-style="western"><surname>Aljami</surname><given-names>HA</given-names></name><name name-style="western"><surname>Alenazi</surname><given-names>MW</given-names></name><name name-style="western"><surname>Alhafufi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aldibasi</surname><given-names>OS</given-names></name><name name-style="western"><surname>Hashem</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kasem</surname><given-names>S</given-names></name><name name-style="western"><surname>Albrahim</surname><given-names>R</given-names></name><name name-style="western"><surname>Aldubaib</surname><given-names>M</given-names></name><name name-style="western"><surname>Almansour</surname><given-names>A</given-names></name><name name-style="western"><surname>Temperton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Abu-Obaidah</surname><given-names>A</given-names></name><name name-style="western"><surname>Alkarar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>IK</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>E</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Bayoumi</surname><given-names>F</given-names></name><name name-style="western"><surname>Aldowerij</surname><given-names>A</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>OH</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>HH</given-names></name></person-group><article-title>Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>16292</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-52730-4</pub-id><pub-id pub-id-type="pmid">31705137</pub-id><pub-id pub-id-type="pmcid">PMC6841732</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Haddock</surname><given-names>E</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>K</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>A</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>PW</given-names></name><name name-style="western"><surname>Saturday</surname><given-names>G</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Clark</surname><given-names>MHA</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques</article-title><source>Sci Adv</source><year>2020</year><volume>6</volume><issue>24</issue><fpage>eaba8399</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aba8399</pub-id><pub-id pub-id-type="pmid">32577525</pub-id><pub-id pub-id-type="pmcid">PMC7286676</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Bittaye</surname><given-names>M</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>FR</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Mair</surname><given-names>C</given-names></name><name name-style="western"><surname>Makinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>J</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>C</given-names></name><name name-style="western"><surname>Halwe</surname><given-names>S</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JO</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N</given-names></name><name name-style="western"><surname>Silman</surname><given-names>D</given-names></name><name name-style="western"><surname>Poulton</surname><given-names>I</given-names></name><name name-style="western"><surname>Datoo</surname><given-names>M</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J</given-names></name><name name-style="western"><surname>Themistocleous</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lawrie</surname><given-names>A</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>R</given-names></name><name name-style="western"><surname>Berrie</surname><given-names>E</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S</given-names></name></person-group><article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><issue>7</issue><fpage>816</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30160-2</pub-id><pub-id pub-id-type="pmid">32325038</pub-id><pub-id pub-id-type="pmcid">PMC7172901</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bittaye</surname><given-names>M</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>EA</given-names></name><name name-style="western"><surname>Dold</surname><given-names>C</given-names></name><name name-style="western"><surname>Faust</surname><given-names>SN</given-names></name><name name-style="western"><surname>Finn</surname><given-names>A</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hallis</surname><given-names>B</given-names></name><name name-style="western"><surname>Heath</surname><given-names>P</given-names></name><name name-style="western"><surname>Jenkin</surname><given-names>D</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>R</given-names></name><name name-style="western"><surname>Makinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H</given-names></name><name name-style="western"><surname>Snape</surname><given-names>M</given-names></name><name name-style="western"><surname>Tarrant</surname><given-names>R</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Green</surname><given-names>C</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AVS</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Oxford</surname><given-names>CVTG</given-names></name></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10249</issue><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>A</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Song</surname><given-names>F</given-names></name><name name-style="western"><surname>Jany</surname><given-names>S</given-names></name><name name-style="western"><surname>Fux</surname><given-names>R</given-names></name><name name-style="western"><surname>Shams-Eldin</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G</given-names></name></person-group><article-title>Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>16</issue><fpage>8651</fpage><lpage>8656</lpage><pub-id pub-id-type="doi">10.1128/JVI.00614-15</pub-id><pub-id pub-id-type="pmid">26018172</pub-id><pub-id pub-id-type="pmcid">PMC4524222</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name><name name-style="western"><surname>van den Brand</surname><given-names>JM</given-names></name><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A</given-names></name><name name-style="western"><surname>Wohlsein</surname><given-names>P</given-names></name><name name-style="western"><surname>Smits</surname><given-names>SL</given-names></name><name name-style="western"><surname>Schipper</surname><given-names>D</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>TM</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N</given-names></name><name name-style="western"><surname>Fux</surname><given-names>R</given-names></name><name name-style="western"><surname>Bensaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Solanes Foz</surname><given-names>D</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>W</given-names></name><name name-style="western"><surname>Segales</surname><given-names>J</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><year>2016</year><volume>351</volume><issue>6268</issue><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.aad1283</pub-id><pub-id pub-id-type="pmid">26678878</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>T</given-names></name><name name-style="western"><surname>Dahlke</surname><given-names>C</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Krahling</surname><given-names>V</given-names></name><name name-style="western"><surname>Okba</surname><given-names>NMA</given-names></name><name name-style="western"><surname>Halwe</surname><given-names>S</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>C</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hesterkamp</surname><given-names>T</given-names></name><name name-style="western"><surname>Jambrecina</surname><given-names>A</given-names></name><name name-style="western"><surname>Borregaard</surname><given-names>S</given-names></name><name name-style="western"><surname>Ly</surname><given-names>ML</given-names></name><name name-style="western"><surname>Zinser</surname><given-names>ME</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>E</given-names></name><name name-style="western"><surname>Poetsch</surname><given-names>JSH</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>R</given-names></name><name name-style="western"><surname>Fux</surname><given-names>R</given-names></name><name name-style="western"><surname>Schmiedel</surname><given-names>S</given-names></name><name name-style="western"><surname>Lohse</surname><given-names>AW</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Addo</surname><given-names>MM</given-names></name></person-group><article-title>Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30248-6</pub-id><pub-id pub-id-type="pmid">32325037</pub-id><pub-id pub-id-type="pmcid">PMC7172913</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name><name name-style="western"><surname>Gopal</surname><given-names>R</given-names></name><name name-style="western"><surname>Yount</surname><given-names>BL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Donaldson</surname><given-names>EF</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Scobey</surname><given-names>TD</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>LE</given-names></name><name name-style="western"><surname>Denison</surname><given-names>MR</given-names></name><name name-style="western"><surname>Zambon</surname><given-names>M</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>7</issue><fpage>995</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit609</pub-id><pub-id pub-id-type="pmid">24253287</pub-id><pub-id pub-id-type="pmcid">PMC3952667</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malczyk</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A</given-names></name><name name-style="western"><surname>Prufer</surname><given-names>S</given-names></name><name name-style="western"><surname>Scheuplein</surname><given-names>VA</given-names></name><name name-style="western"><surname>Hutzler</surname><given-names>S</given-names></name><name name-style="western"><surname>Kreuz</surname><given-names>D</given-names></name><name name-style="western"><surname>Beissert</surname><given-names>T</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Hubich-Rau</surname><given-names>S</given-names></name><name name-style="western"><surname>Tondera</surname><given-names>C</given-names></name><name name-style="western"><surname>Eldin</surname><given-names>HS</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J</given-names></name><name name-style="western"><surname>Vergara-Alert</surname><given-names>J</given-names></name><name name-style="western"><surname>Suzer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Seifried</surname><given-names>J</given-names></name><name name-style="western"><surname>Hanschmann</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kalinke</surname><given-names>U</given-names></name><name name-style="western"><surname>Herold</surname><given-names>S</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Cichutek</surname><given-names>K</given-names></name><name name-style="western"><surname>Waibler</surname><given-names>Z</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Muhlebach</surname><given-names>MD</given-names></name></person-group><article-title>A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>22</issue><fpage>11654</fpage><lpage>11667</lpage><pub-id pub-id-type="doi">10.1128/JVI.01815-15</pub-id><pub-id pub-id-type="pmid">26355094</pub-id><pub-id pub-id-type="pmcid">PMC4645655</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirblich</surname><given-names>C</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>D</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>TS</given-names></name><name name-style="western"><surname>Bernbaum</surname><given-names>JG</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>LE</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RF</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></name><name name-style="western"><surname>Schnell</surname><given-names>MJ</given-names></name></person-group><article-title>One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus</article-title><source>J Virol</source><year>2017</year><volume>91</volume><issue>2</issue><fpage>e02040-16</fpage><pub-id pub-id-type="doi">10.1128/JVI.02040-16</pub-id><pub-id pub-id-type="pmid">27807241</pub-id><pub-id pub-id-type="pmcid">PMC5215356</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>RQ</given-names></name><name name-style="western"><surname>Ge</surname><given-names>JY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wen</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Bu</surname><given-names>ZG</given-names></name></person-group><article-title>Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels</article-title><source>J Integr Agric</source><year>2017</year><volume>16</volume><issue>10</issue><fpage>2264</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1016/S2095-3119(17)61660-5</pub-id><pub-id pub-id-type="pmid">32288953</pub-id><pub-id pub-id-type="pmcid">PMC7128255</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>L</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bu</surname><given-names>Z</given-names></name></person-group><article-title>A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization</article-title><source>Antiviral Res</source><year>2018</year><volume>150</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.12.007</pub-id><pub-id pub-id-type="pmid">29246504</pub-id><pub-id pub-id-type="pmcid">PMC7113862</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takasuka</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>M</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Itamura</surname><given-names>S</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ohnishi</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohshima</surname><given-names>M</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Odagiri</surname><given-names>T</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshikura</surname><given-names>H</given-names></name><name name-style="western"><surname>Takemori</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name></person-group><article-title>A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice</article-title><source>Int Immunol</source><year>2004</year><volume>16</volume><issue>10</issue><fpage>1423</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh143</pub-id><pub-id pub-id-type="pmid">15314040</pub-id><pub-id pub-id-type="pmcid">PMC7108621</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>NS</given-names></name><name name-style="western"><surname>Lu</surname><given-names>LW</given-names></name><name name-style="western"><surname>Xie</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wen</surname><given-names>YM</given-names></name></person-group><article-title>Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>7</issue><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.07.031</pub-id><pub-id pub-id-type="pmid">15603894</pub-id><pub-id pub-id-type="pmcid">PMC7115388</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>JT</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Su</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>JG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YX</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>YP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>RH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Hai</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HX</given-names></name><name name-style="western"><surname>Li</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kan</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>GM</given-names></name><name name-style="western"><surname>An</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Yin</surname><given-names>WD</given-names></name><name name-style="western"><surname>Dongs</surname><given-names>XP</given-names></name></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antivir Ther</source><year>2007</year><volume>12</volume><issue>7</issue><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K</given-names></name><name name-style="western"><surname>Peng</surname><given-names>BH</given-names></name><name name-style="western"><surname>Couch</surname><given-names>RB</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><issue>9</issue><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmid">27269431</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title><source>Emerg Microbes Infect</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>60</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0056-7</pub-id><pub-id pub-id-type="pmid">29618723</pub-id><pub-id pub-id-type="pmcid">PMC5884803</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minor</surname><given-names>PD</given-names></name></person-group><article-title>Live attenuated vaccines: historical successes and current challenges</article-title><source>Virology</source><year>2015</year><volume>479&#8211;480</volume><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.03.032</pub-id><pub-id pub-id-type="pmid">25864107</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>ML</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>JP</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>E</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>SR</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name></person-group><article-title>A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>15</issue><fpage>7721</fpage><lpage>7724</lpage><pub-id pub-id-type="doi">10.1128/JVI.00304-08</pub-id><pub-id pub-id-type="pmid">18463152</pub-id><pub-id pub-id-type="pmcid">PMC2493341</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>HD</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>KH</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name><name name-style="western"><surname>Yount</surname><given-names>BL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>McAnarney</surname><given-names>ET</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Waters</surname><given-names>KM</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Combination attenuation offers strategy for live attenuated coronavirus vaccines</article-title><source>J Virol</source><year>2018</year><volume>92</volume><issue>17</issue><fpage>e00710</fpage><lpage>e718</lpage><pub-id pub-id-type="doi">10.1128/JVI.00710-18</pub-id><pub-id pub-id-type="pmid">29976657</pub-id><pub-id pub-id-type="pmcid">PMC6096805</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>HD</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>KH</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name><name name-style="western"><surname>Yount</surname><given-names>BL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>McAnarney</surname><given-names>ET</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>KG</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>AS</given-names></name><name name-style="western"><surname>Debbink</surname><given-names>K</given-names></name><name name-style="western"><surname>Sims</surname><given-names>AC</given-names></name><name name-style="western"><surname>Waters</surname><given-names>KM</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Middle East Respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis</article-title><source>mSphere</source><year>2017</year><volume>2</volume><issue>6</issue><fpage>e00346-17</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00346-17</pub-id><pub-id pub-id-type="pmid">29152578</pub-id><pub-id pub-id-type="pmcid">PMC5687918</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name><name name-style="western"><surname>Becker</surname><given-names>MM</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>LD</given-names></name><name name-style="western"><surname>Bolles</surname><given-names>M</given-names></name><name name-style="western"><surname>Denison</surname><given-names>MR</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><issue>12</issue><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1038/nm.2972</pub-id><pub-id pub-id-type="pmid">23142821</pub-id><pub-id pub-id-type="pmcid">PMC3518599</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoeman</surname><given-names>D</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>BC</given-names></name></person-group><article-title>Coronavirus envelope protein: current knowledge</article-title><source>Virol J</source><year>2019</year><volume>16</volume><issue>1</issue><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmid">31133031</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeDiego</surname><given-names>ML</given-names></name><name name-style="western"><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jimenez-Guardeno</surname><given-names>JM</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>JA</given-names></name><name name-style="western"><surname>Castano-Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><name name-style="western"><surname>Usera</surname><given-names>F</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></name></person-group><article-title>Coronavirus virulence genes with main focus on SARS-CoV envelope gene</article-title><source>Virus Res</source><year>2014</year><volume>194</volume><fpage>124</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.07.024</pub-id><pub-id pub-id-type="pmid">25093995</pub-id><pub-id pub-id-type="pmcid">PMC4261026</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></name><name name-style="western"><surname>Debbink</surname><given-names>K</given-names></name><name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments</article-title><source>Virus Res</source><year>2014</year><volume>194</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.09.009</pub-id><pub-id pub-id-type="pmid">25278144</pub-id><pub-id pub-id-type="pmcid">PMC4260984</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>F</given-names></name><name name-style="western"><surname>Khan</surname><given-names>KS</given-names></name><name name-style="western"><surname>Le</surname><given-names>TK</given-names></name><name name-style="western"><surname>Paris</surname><given-names>C</given-names></name><name name-style="western"><surname>Demirbag</surname><given-names>S</given-names></name><name name-style="western"><surname>Barfuss</surname><given-names>P</given-names></name><name name-style="western"><surname>Rocchi</surname><given-names>P</given-names></name><name name-style="western"><surname>Ng</surname><given-names>WL</given-names></name></person-group><article-title>Coronavirus RNA proofreading: molecular basis and therapeutic targeting</article-title><source>Mol Cell</source><year>2020</year><volume>79</volume><issue>5</issue><fpage>710</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.07.027</pub-id><pub-id pub-id-type="pmid">32853546</pub-id><pub-id pub-id-type="pmcid">PMC7402271</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Riel</surname><given-names>D</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name></person-group><article-title>Next-generation vaccine platforms for COVID-19</article-title><source>Nat Mater</source><year>2020</year><volume>19</volume><issue>8</issue><fpage>810</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0746-0</pub-id><pub-id pub-id-type="pmid">32704139</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J</given-names></name></person-group><article-title>Developing covid-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>21</issue><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Johnson-&amp;-Johnson. Johnson &amp; Johnson announces a lead vaccine candidate for COVID-19; landmark new partnership with U.S. Department of Health &amp; Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use. 2020.</mixed-citation></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">GSK. GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations. 2020.</mixed-citation></ref><ref id="CR126"><label>126.</label><mixed-citation publication-type="other">Chemical-&amp;-Engineering-News. Moderna picks Lonza to make 1 billion doses of its coronavirus vaccine. 2020.</mixed-citation></ref><ref id="CR127"><label>127.</label><mixed-citation publication-type="other">CNN-Health. US taxpayers are funding six Covid vaccines. Here's how they work. 2020.</mixed-citation></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">REUTERS. EU to use $2.7 billion fund to buy promising COVID-19 vaccines. 2020.</mixed-citation></ref><ref id="CR129"><label>129.</label><mixed-citation publication-type="other">AP-News. China aims to make 1 billion COVID-19 vaccine doses a year. 2020.</mixed-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World-Health-Organization</collab></person-group><source>Draft landscape of COVID-19 candidate vaccines</source><year>2020</year><publisher-loc>Geneva</publisher-loc><publisher-name>World-Health-Organization</publisher-name></element-citation></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Novavax. NVX-CoV2373 COVID-19 Vaccine candidate phase 1/2, part 1, clinical trial results. 2020.</mixed-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S</given-names></name><name name-style="western"><surname>Plested</surname><given-names>JS</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cloney-Clark</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>RE</given-names></name><name name-style="western"><surname>Logue</surname><given-names>J</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>M</given-names></name><name name-style="western"><surname>Weston</surname><given-names>S</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>PA</given-names></name><name name-style="western"><surname>Desai</surname><given-names>C</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>K</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M</given-names></name><name name-style="western"><surname>Price-Abbott</surname><given-names>P</given-names></name><name name-style="western"><surname>Formica</surname><given-names>N</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>V</given-names></name><name name-style="western"><surname>Fries</surname><given-names>L</given-names></name><name name-style="western"><surname>Lickliter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>P</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>B</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></name></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E</given-names></name><name name-style="western"><surname>An</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ke</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>3</issue><fpage>722</fpage><lpage>733 e711</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.035</pub-id><pub-id pub-id-type="pmid">32645327</pub-id><pub-id pub-id-type="pmcid">PMC7321023</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diehl</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JC</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>SE</given-names></name><name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AS</given-names></name><name name-style="western"><surname>Giffear</surname><given-names>M</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>NY</given-names></name><name name-style="western"><surname>Bagarazzi</surname><given-names>ML</given-names></name></person-group><article-title>Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers</article-title><source>Hum Vaccin Immunother</source><year>2013</year><volume>9</volume><issue>10</issue><fpage>2246</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.4161/hv.24702</pub-id><pub-id pub-id-type="pmid">24051434</pub-id><pub-id pub-id-type="pmcid">PMC3906411</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Walters</surname><given-names>J</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K</given-names></name><name name-style="western"><surname>Parzych</surname><given-names>E</given-names></name><name name-style="western"><surname>Gary</surname><given-names>EN</given-names></name><name name-style="western"><surname>Maricic</surname><given-names>I</given-names></name><name name-style="western"><surname>Purwar</surname><given-names>M</given-names></name><name name-style="western"><surname>Eblimit</surname><given-names>Z</given-names></name><name name-style="western"><surname>Walker</surname><given-names>SN</given-names></name><name name-style="western"><surname>Guimet</surname><given-names>D</given-names></name><name name-style="western"><surname>Bhojnagarwala</surname><given-names>P</given-names></name><name name-style="western"><surname>Doan</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D</given-names></name><name name-style="western"><surname>Reeder</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pessaint</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KY</given-names></name><name name-style="western"><surname>Cook</surname><given-names>A</given-names></name><name name-style="western"><surname>Chokkalingam</surname><given-names>N</given-names></name><name name-style="western"><surname>Finneyfrock</surname><given-names>B</given-names></name><name name-style="western"><surname>Tello-Ruiz</surname><given-names>E</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>A</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Generotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>J</given-names></name><name name-style="western"><surname>Tursi</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>VM</given-names></name><name name-style="western"><surname>Dia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>FI</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MG</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Humeau</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>TRF</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>KE</given-names></name></person-group><article-title>Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.28.225649</pub-id><pub-id pub-id-type="pmid">34604818</pub-id><pub-id pub-id-type="pmcid">PMC8479327</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><mixed-citation publication-type="other">INOVIO-Pharmaceuticals. INOVIO announces positive interim phase 1 data for INO-4800 vaccine for COVID-19. 2020.&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx">http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx</ext-link>.</mixed-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauffman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Webber</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name></person-group><article-title>Materials for non-viral intracellular delivery of messenger RNA therapeutics</article-title><source>J Control Release</source><year>2016</year><volume>240</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.032</pub-id><pub-id pub-id-type="pmid">26718856</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Kariko</surname><given-names>K</given-names></name><name name-style="western"><surname>Tureci</surname><given-names>O</given-names></name></person-group><article-title>mRNA-based therapeutics&#8211;developing a new class of drugs</article-title><source>Nat Rev Drug Discov</source><year>2014</year><volume>13</volume><issue>10</issue><fpage>759</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/nrd4278</pub-id><pub-id pub-id-type="pmid">25233993</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines&#8212;a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><issue>4</issue><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson 2nd PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH, m RNASG</collab></person-group><article-title>An mRNA vaccine against SARS-CoV-2&#8212;preliminary report</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><mixed-citation publication-type="other">Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson 2nd PA, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH, m RNASG. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020.&#160;10.1056/NEJMoa2028436.</mixed-citation></ref><ref id="CR142"><label>142.</label><mixed-citation publication-type="other">Moderna&#8217;s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.<italic toggle="yes"> Moderna</italic>, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy">https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy</ext-link>.</mixed-citation></ref><ref id="CR143"><label>143.</label><mixed-citation publication-type="other">Genetic-Engineering-&amp;-Biotechnology-News. BioNTech, Pfizer, and Fosun Pharma&#8212;BNT162. Genetic Engineering &amp; Biotechnology News. 2020.</mixed-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K</given-names></name><name name-style="western"><surname>Raabe</surname><given-names>V</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Koury</surname><given-names>K</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>W</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>PY</given-names></name><name name-style="western"><surname>Tureci</surname><given-names>O</given-names></name><name name-style="western"><surname>Tompkins</surname><given-names>KR</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>WC</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name></person-group><article-title>Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M</given-names></name><name name-style="western"><surname>Baum</surname><given-names>A</given-names></name><name name-style="western"><surname>Pascal</surname><given-names>K</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>J</given-names></name><name name-style="western"><surname>Maurus</surname><given-names>D</given-names></name><name name-style="western"><surname>Brachtendorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Lorks</surname><given-names>V</given-names></name><name name-style="western"><surname>Sikorski</surname><given-names>J</given-names></name><name name-style="western"><surname>Hilker</surname><given-names>R</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D</given-names></name><name name-style="western"><surname>Eller</surname><given-names>AK</given-names></name><name name-style="western"><surname>Grutzner</surname><given-names>J</given-names></name><name name-style="western"><surname>Boesler</surname><given-names>C</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuhnle</surname><given-names>MC</given-names></name><name name-style="western"><surname>Luxemburger</surname><given-names>U</given-names></name><name name-style="western"><surname>Kemmer-Bruck</surname><given-names>A</given-names></name><name name-style="western"><surname>Langer</surname><given-names>D</given-names></name><name name-style="western"><surname>Bexon</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolte</surname><given-names>S</given-names></name><name name-style="western"><surname>Kariko</surname><given-names>K</given-names></name><name name-style="western"><surname>Palanche</surname><given-names>T</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>B</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>A</given-names></name><name name-style="western"><surname>Shi</surname><given-names>PY</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>C</given-names></name><name name-style="western"><surname>Perez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Loschko</surname><given-names>J</given-names></name><name name-style="western"><surname>Scully</surname><given-names>IL</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>W</given-names></name><name name-style="western"><surname>Kyratsous</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>PR</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Tureci</surname><given-names>O</given-names></name></person-group><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2814-7</pub-id><pub-id pub-id-type="pmid">32998157</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Koury</surname><given-names>K</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>W</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>PY</given-names></name><name name-style="western"><surname>Tureci</surname><given-names>O</given-names></name><name name-style="western"><surname>Tompkins</surname><given-names>KR</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Raabe</surname><given-names>V</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>PR</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>WC</given-names></name></person-group><article-title>Safety and immunogenicity of two RNA-based covid-19 vaccine candidates</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/nejmoa2027906</pub-id><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><mixed-citation publication-type="other">Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. <italic toggle="yes">Pfizer</italic>, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine</ext-link>.</mixed-citation></ref><ref id="CR148"><label>148.</label><mixed-citation publication-type="other">The-New-York-Times. AstraZeneca Pauses Vaccine Trial for Safety Review. 2020.</mixed-citation></ref><ref id="CR149"><label>149.</label><mixed-citation publication-type="other">Astrazeneca. COVID-19 vaccine AZD1222 clinical trials resumed in the UK. 2020.</mixed-citation></ref><ref id="CR150"><label>150.</label><mixed-citation publication-type="other">AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. <italic toggle="yes">Astrazeneca</italic>, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html">https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html</ext-link>.</mixed-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><name name-style="western"><surname>Tukhvatullin</surname><given-names>AI</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>DM</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>AV</given-names></name><name name-style="western"><surname>Botikov</surname><given-names>AG</given-names></name><name name-style="western"><surname>Izhaeva</surname><given-names>FM</given-names></name><name name-style="western"><surname>Popova</surname><given-names>O</given-names></name><name name-style="western"><surname>Ozharovskaya</surname><given-names>TA</given-names></name><name name-style="western"><surname>Esmagambetov</surname><given-names>IB</given-names></name><name name-style="western"><surname>Favorskaya</surname><given-names>IA</given-names></name><name name-style="western"><surname>Zrelkin</surname><given-names>DI</given-names></name><name name-style="western"><surname>Voronina</surname><given-names>DV</given-names></name><name name-style="western"><surname>Shcherbinin</surname><given-names>DN</given-names></name><name name-style="western"><surname>Semikhin</surname><given-names>AS</given-names></name><name name-style="western"><surname>Simakova</surname><given-names>YV</given-names></name><name name-style="western"><surname>Tokarskaya</surname><given-names>EA</given-names></name><name name-style="western"><surname>Lubenets</surname><given-names>NL</given-names></name><name name-style="western"><surname>Egorova</surname><given-names>DA</given-names></name><name name-style="western"><surname>Shmarov</surname><given-names>MM</given-names></name><name name-style="western"><surname>Nikitenko</surname><given-names>NA</given-names></name><name name-style="western"><surname>Morozova</surname><given-names>LF</given-names></name><name name-style="western"><surname>Smolyarchuk</surname><given-names>EA</given-names></name><name name-style="western"><surname>Kryukov</surname><given-names>EV</given-names></name><name name-style="western"><surname>Babira</surname><given-names>VF</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>SV</given-names></name><name name-style="western"><surname>Naroditsky</surname><given-names>BS</given-names></name><name name-style="western"><surname>Gintsburg</surname><given-names>AL</given-names></name></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10255</issue><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Second Interim Analysis of Clinical Trial Data Showed a 91.4% Efficacy for the Sputnik V Vaccine on Day 28 After the First Dose; Vaccine Efficacy is Over 95% 42 Days After the First Dose. <italic toggle="yes">Sputnik V</italic>, 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/">https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/</ext-link>.</mixed-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Kan</surname><given-names>B</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>F</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Lou</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><year>2020</year><volume>369</volume><issue>6499</issue><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>You</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title><source>JAMA</source><year>2020</year><volume>324</volume><issue>10</issue><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>W</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>3</issue><fpage>713</fpage><lpage>721 e719</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.008</pub-id><pub-id pub-id-type="pmid">32778225</pub-id><pub-id pub-id-type="pmcid">PMC7275151</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>You</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><mixed-citation publication-type="other">AIVITA-Biomedical. SARS-COV-2 VACCINE. 2020.</mixed-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>LK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>XM</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LK</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name></person-group><article-title>Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-00197-3</pub-id><pub-id pub-id-type="pmid">32802404</pub-id><pub-id pub-id-type="pmcid">PMC7406496</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stensballe</surname><given-names>LG</given-names></name><name name-style="western"><surname>Nante</surname><given-names>E</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>IP</given-names></name><name name-style="western"><surname>Kofoed</surname><given-names>PE</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>A</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>H</given-names></name><name name-style="western"><surname>Newport</surname><given-names>M</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name></person-group><article-title>Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>10</issue><fpage>1251</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.006</pub-id><pub-id pub-id-type="pmid">15652667</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>R</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>RH</given-names></name></person-group><article-title>Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin</article-title><source>J Infect Dis</source><year>1977</year><volume>136</volume><issue>2</issue><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1093/infdis/136.2.171</pub-id><pub-id pub-id-type="pmid">894076</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>SE</given-names></name><name name-style="western"><surname>Visintine</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tomeh</surname><given-names>MO</given-names></name><name name-style="western"><surname>Nahmias</surname><given-names>AJ</given-names></name></person-group><article-title>Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection</article-title><source>Proc Soc Exp Biol Med</source><year>1976</year><volume>152</volume><issue>1</issue><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3181/00379727-152-39327</pub-id><pub-id pub-id-type="pmid">177992</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Neill</surname><given-names>LAJ</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group><article-title>BCG-induced trained immunity: can it offer protection against COVID-19?</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0337-y</pub-id><pub-id pub-id-type="pmid">32393823</pub-id><pub-id pub-id-type="pmcid">PMC7212510</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name><name name-style="western"><surname>Reandelar</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Fasciglione</surname><given-names>K</given-names></name><name name-style="western"><surname>Roumenova</surname><given-names>V</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Otazu</surname><given-names>GH</given-names></name></person-group><article-title>Correlation between universal BCG vaccination policy and reduced mortality for COVID-19</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.24.20042937</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>WC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>PH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>JH</given-names></name></person-group><article-title>Disappearance of antibodies to SARS-associated coronavirus after recovery</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><issue>11</issue><fpage>1162</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1056/NEJMc070348</pub-id><pub-id pub-id-type="pmid">17855683</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>LP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>NC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Tian</surname><given-names>XY</given-names></name><name name-style="western"><surname>Na</surname><given-names>DY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LY</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LF</given-names></name><name name-style="western"><surname>Liang</surname><given-names>GD</given-names></name></person-group><article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title><source>Emerg Infect Dis</source><year>2007</year><volume>13</volume><issue>10</issue><fpage>1562</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.3201/eid1310.070576</pub-id><pub-id pub-id-type="pmid">18258008</pub-id><pub-id pub-id-type="pmcid">PMC2851497</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><article-title>What reinfections mean for COVID-19</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30783-0</pub-id><pub-id pub-id-type="pmid">33058796</pub-id><pub-id pub-id-type="pmcid">PMC7550040</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>JH</given-names></name><name name-style="western"><surname>Joo</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Baek</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WD</given-names></name><name name-style="western"><surname>Jee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Shon</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YK</given-names></name><name name-style="western"><surname>Peck</surname><given-names>KR</given-names></name></person-group><article-title>Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><issue>7</issue><fpage>2268</fpage><pub-id pub-id-type="doi">10.3390/jcm9072268</pub-id><pub-id pub-id-type="pmid">32708872</pub-id><pub-id pub-id-type="pmcid">PMC7408950</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name></person-group><article-title>The coronavirus is mutating&#8212;does it matter?</article-title><source>Nature</source><year>2020</year><volume>585</volume><issue>7824</issue><fpage>174</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-02544-6</pub-id><pub-id pub-id-type="pmid">32901123</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>WM</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J</given-names></name><name name-style="western"><surname>Abfalterer</surname><given-names>W</given-names></name><name name-style="western"><surname>Hengartner</surname><given-names>N</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>EE</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>T</given-names></name><name name-style="western"><surname>Foley</surname><given-names>B</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>KM</given-names></name><name name-style="western"><surname>Parker</surname><given-names>MD</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>DG</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CM</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>TM</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>TI</given-names></name><name name-style="western"><surname>Sheffield</surname><given-names>C-GG</given-names></name><name name-style="western"><surname>McDanal</surname><given-names>C</given-names></name><name name-style="western"><surname>Perez</surname><given-names>LG</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Moon-Walker</surname><given-names>A</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>SP</given-names></name><name name-style="western"><surname>LaBranche</surname><given-names>CC</given-names></name><name name-style="western"><surname>Saphire</surname><given-names>EO</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name></person-group><article-title>Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>4</issue><fpage>812</fpage><lpage>827 e819</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id><pub-id pub-id-type="pmcid">PMC7332439</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>CB</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>A</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>ES</given-names></name><name name-style="western"><surname>Izard</surname><given-names>T</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H</given-names></name></person-group><article-title>The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.12.148726</pub-id><pub-id pub-id-type="pmid">33330870</pub-id><pub-id pub-id-type="pmcid">PMC7743078</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><mixed-citation publication-type="other">Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG. Remdesivir for the treatment of covid-19&#8212;final report. N Engl J Med. 2020. 10.1056/NEJMoa2007764</mixed-citation></ref><ref id="CR172"><label>172.</label><mixed-citation publication-type="other">Group R.C., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S.N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. Dexamethasone in hospitalized patients with covid-19&#8212;preliminary report. N Engl J Med. 2020. 10.1056/NEJMoa2021436.</mixed-citation></ref></ref-list></back></article></pmc-articleset>